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SUMMARY 
The ability to perceive pain is a basic property of humans and of all other higher order 
animals. The primary role of pain sensation and nociception (that is, the neuronal activity 
encoding pain) is to protect against potentially harmful threats arriving from the environment 
or the body interior. Pain can however also become dysfunctional and persist for extended 
periods of time without an apparent benefit, instead becoming a major burden that requires 
medical attention. Chronic pain is a major socio-economic challenge, which – despite 
scientific advances in the understanding of its causes – remains poorly responsive to the 
drugs available on the market today. Recent insights into the mechanisms of chronic pain 
states suggest that a common factor for many kinds of persistent pain states is a loss of 
inhibition in spinal cord circuits that normally control nociceptive input to the brain. The so-
called benzodiazepines – first marketed by Hoffmann-La Roche in the 1960s – are drugs that 
facilitate synaptic inhibition throughout the CNS and have as such the potential to reverse 
pathological disinhibition. Benzodiazepines facilitate inhibition by increasing the activity of 
γ-aminobutyric acid (GABA) at its receptor, a heteropentameric anion permeable ion 
channel. Although rodent studies have shown that pathologically increased pain sensitivity 
can be normalized by intrathecal (spinal) injection of benzodiazepines, these drugs do not 
exert clinically relevant analgesia in human patients, at least not after systemic application.  
In this thesis, I have tested the hypothesis that benzodiazepines reverse pathological pain 
after systemic application if their action is restricted to well-defined subtypes of GABAA 
receptors. Using GABAA receptor point-mutated mice, I was able to demonstrate that 
selective targeting of GABAA receptors that contain the α2 subunit (α2-GABAA) receptors 
evoke pronounced pain relief in the absence of confounding and undesired sedation. I could 
also confirm previous findings that had proposed that activation of the same GABAA 
receptors induces anxiolysis and muscle relaxation. Importantly, selective targeting of α2-
GABAA receptors avoided several unwanted effects of classical non-selective 
benzodiazepines including sedation, impairment of motor coordination, and the progressive 
loss of therapeutic efficacy over time. Using mice in which the action of classical 
benzodiazepine agonists was restricted to only a single GABAA receptor subtype, I could also 
propose a new hypothesis explaining why classical benzodiazepines lack clinically relevant 
analgesic properties. For two clinically used benzodiazepines (diazepam and midazolam), I 
could demonstrate that strong α1-GABAA receptor-mediated sedation occurs already at doses 
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more than 20 times lower that those required for significant analgesia. Dose limiting sedation 
is therefore the likely reason for the lack of clinically relevant analgesia in human pain 
patients.  
The second part of the thesis project has been designed to foster the translation of the results 
of the first project to clinical application. Within recent years, drug companies have 
developed benzodiazepine site agonists with improved subtype specificity (that is, with 
reduced activity at α1-GABAA receptors). So far, none of these compounds is generally 
available for tests in humans, prompting for alternative strategies to obtain proof-of-concept 
evidence. A previous report has suggested that N-desmethyl clobazam (NDMC), a major 
metabolite of the clinically used benzodiazepine clobazam, may have a pharmacological 
profile more favorable than that of most classical benzodiazepines. We found that NDMC 
indeed possesses an improved α2 versus α1-GABAA receptor selectivity in vitro, and 
pronounced antihyperalgesic efficacy at doses that do not induce apparent sedation or 
impairment of motor coordination in mice. In the light of this favorable pharmacological 
profile and given the fact that new unexpected side effects are highly unlikely to occur in a 
metabolite of a clinically used benzodiazepine, NDMC should be well-suited for proof-of-
concept trials in human volunteers or pain patients. 
The results of this thesis thus provide further support for a potential use of α2-selective 
GABAA receptor modulators as novel analgesics. 
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ZUSAMMENFASSUNG 
Schmerzwahrnehmung ist eine grundlegende Fähigkeit des Menschen und aller höheren 
Tiere. Die primäre Funktion des Schmerzes und der Nociception (d.h. der neuronalen 
Kodierung von Schmerz) ist der Schutz vor potentieller Gewebeschädigung durch exogene 
oder endogene Einflüsse. Schmerzen können sich jedoch auch zu einer Fehlfunktion des 
Körpers entwickeln und über längere Zeit ohne offensichtlichen Nutzen bestehen bleiben. 
Schmerzen werden dann zu einer schweren Belastung für das Wohlbefinden der Betroffenen. 
Obwohl bedeutende Fortschritte in unserem Verständnis der biologischen Ursachen 
chronischer Schmerzen gemacht wurden, ist ihre Pharmakotherapie immer noch 
unbefriedigend. Relativ kürzlich gewonnene Einsichten in die zugrunde liegenden 
Mechanismen legen nahe, dass viele Formen persistierender Schmerzen mit einer 
Verminderung der synaptischen Hemmung in spinalen Schmerz verarbeitenden Schaltkreisen 
einhergehen. Benzodiazepine, die erstmals von der Firma Roche in den 1960er Jahren auf 
den Markt gebracht wurden, sind Medikamente, die die synaptische Hemmung in den 
meisten Arealen des ZNS verstärken, indem sie die Bindung des hemmenden 
Neurotransmitters γ-Aminobuttersäure (GABA) an seine Rezeptoren, die GABAA 
Rezeptoren, erhöht. Solche Substanzen sollten grundsätzlich in der Lage sein, eine 
pathologisch verminderte synaptische Hemmung zu korrigieren. Obwohl Studien in Nagern 
tatsächlich gezeigt haben, dass pathologisch gesteigerte Schmerzempfindlichkeit durch 
intrathekal injizierte Benzodiazepine normalisiert werden kann, vermitteln diese Wirkstoffe 
beim Patienten keine klinisch relevante Analgesie.  
In dieser Arbeit wurde untersucht, ob Benzodiazepine nach systemischer Applikation gegen 
pathologische Schmerzen wirksam sind, wenn ihre Wirkung auf bestimmte Subtypen von 
GABAA Rezeptoren beschränkt wird. Mit Hilfe von GABAA Rezeptor-punktmutierten 
Mäusen konnte gezeigt werden, dass selektive Aktivierung von α2-GABAA Rezeptoren eine 
ausgeprägte Analgesie hervorruft, ohne gleichzeitig unerwünschte und die Ergebnisse 
verfälschende Sedation hervorzurufen. Die neuen Ergebnisse bestätigen zudem, dass die 
Aktivierung derselben Rezeptoren auch anxiolytisch und muskelrelaxierend wirkt. Die 
Beschränkung der Wirkung auf α2-GABAA Rezeptoren erlaubt ausserdem mehrere 
unerwünschte Wirkungen von klassischen nicht-selektiven Benzodiazepinen zu vermeiden, 
einschliesslich Sedation, Beeinträchtigung der Motorkoordination, und Toleranzentwicklung 
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(d.h. den allmählichen Wirkungsverlust während chronischer Behandlung). Experimente mit 
diesen und weiteren Mäusen, bei denen die Wirkung von klassischen Benzodiazepinen auf 
einen einzigen GABAA Rezeptorsubtyp beschränkt war, konnten zudem eine Erklärung dafür 
liefern, warum mit klassischen Benzodiazepinen keine klinisch relevante Analgesie erzielt 
werden kann. Am Beispiel der beiden klassischen Benzodiazepine Diazepam und Midazolam 
konnte gezeigt werden, dass α1-GABAA Rezeptor-vermittelte Sedation bereits in 
Dosierungen auftritt, die 20-fach unter denen liegen, die für eine signifikante Analgesie 
benötigt werden. Die durch klassische Benzodiazepine hervorgerufene Sedation verhindert 
somit, dass analgetisch wirksame Dosen unter therapeutischen Bedingungen verabreicht 
werden können.  
Der zweite Teil dieses Projekts widmete sich der Translation der Ergebnisse des ersten 
Projekts in Richtung auf eine klinische Anwendung. Pharmazeutische Firmen haben in den 
letzten Jahren einige Benzodiazepinrezeptoragonisten mit verbesserter Subtyp-Selektivität 
(d.h. mit verminderter Aktivität an α1-GABAA Rezeptoren) entwickelt. Bisher ist keine 
dieser Substanzen für Studien am Menschen allgemein verfügbar, was die Suche nach 
Alternativen für „proof-of-concept“ Studien veranlasst hat. Eine frühere Arbeit berichtete, 
dass N-Desmethylclobazam (NDMC), einer der Hauptmetaboliten des klinisch verwendeten 
Clobazam, ein bessere pharmakologisches Profil haben könnte als die meisten klassischen 
Benzodiazepine. In der vorliegenden Arbeit konnte gezeigt werden, dass NDMC in vitro 
tatsächlich α2-GABAA Rezeptoren stärker aktiviert als α1-GABAA Rezeptoren. In 
Verhaltenstestes an Wildtypmäusen zeigte NDMC darüber hinaus eine ausgeprägte 
analgetische Wirksamkeit in Dosierungen, die keine offensichtliche Sedation oder 
Beeinträchtigung der Motorkoordination verursachten. Angesichts dieses besseren 
pharmakologischen Profils und unter Berücksichtigung der Tatsache, dass das Auftreten von 
neuen, mit Clobazam nicht beobachteten unerwünschten Wirkungen unwahrscheinlich ist, 
sollte NDMC eine für „proof-of-concept“ Studien am Menschen geeignete Substanz sein. 
Zusammenfassend unterstützen die Ergebnisse dieser Dissertation eine mögliche 
Verwendung von selektiven α2-GABAA Rezeptormodulatoren als neuartige Analgetika. 
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ABBREVIATIONS AND CHEMICAL NAMES 
5-HT, 5-hydroxytryptamine 
AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
BDNF, brain-derived neurotrophic factor 
BOLD, blood oxygenation level dependent  
CCI, chronic constriction injury 
CFA, complete Freund’s adjuvant 
CGRP, calcitonin gene related peptide 
COX, cyclooxygenase 
CTB, cholera toxin B subunit 
DMCM, methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate 
DRG, dorsal root ganglion 
EP2, prostaglandin E receptor type 2 
fMRI, functional magnetic resonance imaging 
GABAAR, γ-aminobutyric acid type A receptor 
GAD, glutamate decarboxylase 
GPCR, G protein coupled receptor 
HDAC, histone deacetylase 
HZ166, ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylate 
IB4, isolectin B4 
IPSC, inhibitory postsynaptic current 
KCC2, potassium chloride transporter 2 
L-838,417, 7-tert-Butyl-3-(2,5-difluoro-phenyl)-6-(2-methyl-2H-[1,2,4]triazol-3-
ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine 
LTD, long-term depression 
LTP, long-term potentiation 
mGluR, metabotropic glutamate receptor 
MK-0343, 7-cyclobutyl-6-(2-methyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2,6-
difluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine 
MRK-409, 7-cyclobutyl-6-(2-methyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2,6-
difluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine 
NDMC, N-desmethyl clobazam 
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NGF, nerve growth factor 
NK1, neurokinin 1 
NMDA, N-methyl D aspartate 
NS11394, 3’-[5-(1-Hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile 
NSAID, non-steroidal anti-inflammatory drug 
PAG, periaqueductal grey 
PG, prostaglandin 
PKA, protein kinase A 
PSNL, partial spinal nerve ligation 
RVM, rostroventromedial medulla 
SNI, spared nerve injury 
SNL, spinal nerve ligation 
SNT, sciatic nerve transection 
SP, substance P 
SSNRI, selective serotonin and noradrenaline re-uptake inhibitor 
TNT, tibial nerve transection 
TPA023, 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-
fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine 
TPA023B, 6,2′-difluoro-5′-[3-(1-hydroxy-1-methylethyl)imidazo[1,2-b][1,2,4]triazin-7-
yl]biphenyl-2-carbonitrile 
trkA, tyrosine receptor kinase A 
TRPA, transient receptor potential ankyrin 
TRPM, transient receptor potential M 
TRPV, transient receptor potential channel vanilloid type 
VGLUT, vesicular glutamate receptor transporter 
αx-GABAAR, GABAA receptor containing the αx subunit  
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GENERAL INTRODUCTION 
PAIN 
Pain is the conscious experience that occurs in our brain as a consequence of nociception. 
Nociception is the response of the peripheral nervous system to encountered harmful stimuli 
in our environment. Such stimuli may be noxious heat or cold, bruising mechanical pressures 
and irritant chemicals. The ability to perceive acute noxious threats increases our chances of 
survival by adding to our awareness and by triggering protective reflexes that occur 
unconsciously and almost instantaneously. For instance, immediately withdrawing a hand 
from a hot plate in the kitchen protects from tissue damage. This is obviously a protective 
feature preserved and refined throughout evolution, as evidenced by a reduced life span of 
patients with congenital insensitivity to pain (Cox et al., 2006). Pain can also turn persistent 
and dysfunctional, causing major debilitation and reduce quality of life. 
	  
Figure 1. Pain pathway – from skin to spinal cord to brain, adapted from (Scholz and Woolf, 2002).  
The thinly myelinated Aδ fibers and unmyelinated C fibers react to various kinds of potentially damaging 
stimuli in the environment. This can be high or low temperatures, liquids with high concentration of protons or 
strong mechanical stress or skin-perforating needles. Receptors responding to these stimuli depolarize the 
peripheral terminal of the primary afferent and send the information along the primary afferent fiber to the 
spinal cord dorsal horn. From here, the information travels up to the brain where the painful sensation 
experienced. Connected nuclei in the brain are subsequently activated, triggering emotional, avoidance and 
other memory-related outcomes. 
INTRODUCTION 
- 8 - 
Pain has been defined in 1979 by John Bonica “as an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage, or described in terms of such 
damage” (Bonica, 1979). Any pain-inducing process occurring before the conscious 
experience of pain is therefore not referred to as pain but nociception. Noxious stimuli such 
as very cold or hot temperatures, intense mechanical stimuli, irritant chemicals, low pH, are 
sensed by dedicated sensory neurons, called primary nociceptors (Figure 1). 
These convert noxious stimuli into electrical signals (first in generator potentials and 
subsequently in action potentials) and relay these signals to the spinal cord or brain stem. 
From there, the information is further relayed to higher CNS areas where the conscious 
experience of pain occurs (Figure 2).	  	  
 
Figure 2. The Neuroaxis of pain, modified from (Fields, 2007). The conscious sensation of pain (3) is 
preceded by spinal nociception (2) and the peripheral nociception (1). The various parts of the nervous system 
are connected via nerves and fibers, and communicate electrically by sending action potentials ↯ to one another. 
	  
Although it is unknown exactly where in the brain a conscious experience occurs, the 
experience of pain involves the cerebral cortex and subcortical nuclei, which encode for the 
different sensory and emotional aspects of pain. The brain regions activated in awake humans 
during a painful stimulation have been studied with the use of non-invasive imaging 
techniques, mainly with functional magnetic resonance imaging (fMRI) (Iannetti and 
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Mouraux, 2010). The brain regions activated during a painful experience are collectively 
called the pain matrix. The following chapters aim to describe in detail the parts of the 
nervous system involved in acute and physiological pain sensation, as well as the changes 
that occur during chronic pain states. 
Acute nociception and pain 
Fibers that only respond to noxious stimuli (high threshold fibers) are called nociceptors. 
Most of them belong to the class of thinly myelinated Aδ fibers or unmyelinated C fibers. By 
contrast, innocuous sensations such as light touch and proprioceptive information are 
conveyed by myelinated Aβ fibers. Exposure to noxious stimuli depolarizes the primary 
nociceptor terminals through the opening of ion channels (Waxman and Zamponi, 2014), 
such as the temperature-sensitive transient receptor potential vanilloid 1 (TRPV1). If the 
activation is strong enough, voltage-gated sodium channels (such as NaV1.8) open and elicit 
an action potential that propagates along the nerve fibers from their sensory nerve terminals 
to the dorsal horn of the spinal cord or the trigeminal nucleus. On their path along the 
sensory fibers action potentials also invade the cell bodies of the sensory nerves located in the 
dorsal root ganglia (DRG) and trigeminal ganglia. In the dorsal horn of the spinal cord, the 
central terminals of primary afferent nerve fibers form chemical synapses with second order 
spinal neurons, where they release the excitatory neurotransmitter L-glutamate into the 
synaptic cleft. The peripheral fibers terminate in various grey matter segments of the spinal 
cord, Rexed’s laminae, named after the Swedish neuroscientist Bror Rexed who stained 
transverse spinal cords from cats and kittens with toluidine blue in 1952 (Rexed, 1952), see 
Figure 3. 
The different nociceptive fibers have distinct properties. C fibers are unmyelinated and 
therefore propagate action potentials more slowly (0.5-2 m/s) than the thinly myelinated Aδ 
fibers (12-30 m/s) to the spinal cord (Markopoulos, 2010). Aδ fibers account for the sharp 
and localized pain sensation while C fibers elicit a slower, dull and more diffuse sensation. 
By use of various biomarkers, C fibers are further subdivided into peptidergic (calcitonin 
gene related peptide, CGRP, or Substance P, SP, positive) and non-peptidergic (isolectin B4, 
IB4 binding) C fibers. By genetically silencing these fiber subgroups, their specific roles in 
pain perception have been investigated. A recent study found that by ablating the peptidergic 
C fibers positive for the CGRPα (but not the CGRPβ) peptide resulted in heat and itch 
sensory deficits (McCoy et al., 2013). 
INTRODUCTION 
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Figure 3. Pain pathways in the dorsal horn of the spinal cord, adapted from (Todd, 2010).  
Left image shows a transverse cross section of half of the lumbar spinal cord stained with the neuronal marker 
NeuN. Right section shows the innervation coming in from the periphery. The peripheral fibers terminate in 
various parts of the dorsal spinal cord, subdivided in lamina I-X. Insert shows overview of the entire spinal cord 
cut transversely. 
Interestingly, the authors also found that the mice became hypersensitive to cold, a common 
symptom in patients suffering from chronic neuropathic pain. Similarly, the non-peptidergic 
group of afferents have been implicated in mechanical (Bogen et al., 2008) and heat (Malin et 
al., 2006) hyperalgesia, as well as in the phenomenon of hyperalgesic priming, a persistent 
increased susceptibility to sensitization by inflammation (Joseph and Levine, 2010). 
Nociceptors are further classified depending on the channels they express and, accordingly, 
on the sensory quality that excites them. For instance, sensitivity to heat partially depends on 
the transient receptor potential channels of the vanilloid type 1 and 2 (TRPV1/2), cold 
sensing comes from transient receptor potential subfamily M member 8 (TRPM8) and/or 
TRPA1, and several chemical irritants by the transient receptor potential subfamily A 
member 1 (TRPA1) (Julius and Basbaum, 2001). Primary sensory neurons also differ in their 
expression of vesicular glutamate transporter subtypes (VGLUTs) 1-3 (Ma, 2014), although 
substantial overlap of VGLUT isoform expression can occur in a single neuron. VGLUT1 is 
expressed in about 40% of DRG neurons including most proprioceptors and low-threshold 
myelinated mechanoreceptors. Roughly 90% of DRG neurons express VGLUT2 including 
those responsive to pain, itch, thermoception, mechanoception. VGLUT3 is expressed in 
about 15% of DRG neurons, probably representing low threshold unmyelinated 
mechanoceptors that form the lanceolate endings around hair follicles in the skin. The 
VGLUT3 positive neurons express neither IB4 nor CGRP, and VGLUT3 was not found in 
myelinated mechanoceptors.  
INTRODUCTION 
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1.1.2 Spinal pain processing 
The primary afferent sensory fibers including nociceptive fibers project from the periphery to 
the dorsal horn of the spinal cord. In the dorsal horn, the different kinds of primary afferent 
fibers terminate in a characteristic pattern ordered in layers (Figure 4). Nociceptive fibers 
terminate in the most superficial laminae of the dorsal horn grey matter, whereas myelinated 
fibers terminate mainly in the deep dorsal horn. The ventral horn harbors interneurons and 
motor neurons that control movement and reflexes (Barry et al., 2014). 
	  
Figure 4. How primary afferents terminate in the dorsal horn of the spinal cord, adapted from (Basbaum 
et al., 2009).  
The nociceptive information from the periphery travels along the primary afferent nerve fiber and terminates in 
an ordered manner in the dorsal horn of the spinal cord. 
	  
Antisera against CGRP for labelling peptidergic fibers and other markers (such as IB4 which 
binds to non-peptidergic fibers) have been used to describe the spinal terminals of primary 
nociceptive fibers in more detail in co-expression studies (Figure 5). The thickly myelinated 
non-nociceptive Aβ fibers are labelled in the deeper laminae with antibodies detecting the 
200 kDa neurofilaments protein NF200 (Belkouch et al., 2014). They can also be identified 
by expression of VGLUT1. In addition, myelinated fibers take up the cholera toxin B subunit 
(CTB) which is transported transganglionically along the peripheral nerve and the dorsal root 
to the spinal cord where the fibers can then be detected with antibodies against CTB (Figure 
5). 
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Figure 5. Distribution of primary afferent terminals in the dorsal horn of the rat spinal cord, modified 
from (Polgár et al., 1999; He et al., 2014; McCoy et al., 2014).  
Left image shows an overview of the Rexed lamina from a mouse whose sciatic nerve was injected with the 
cholera toxin B subunit to label axons and terminals of myelinated sensory nerve fibers in the dorsal horn 
(boxed area) and motorneurons in the ventral horn. The middle image shows a triple staining using a CGRP 
antibody to detect peptidergic terminals in the dorsal horn in red, together with Alexa488-conjugated IB4 to 
detect non-peptidergic terminals in green and an antibody against PKCγ in blue. CGRP corresponds to lamina I 
and dorsally superficial lamina II (II outer, IIo). IB4 termination is seen in deeper lamina II (II inner, Iii). PKCγ 
immunoreactivity is mainly observed in the deeper lamina IIi to III. The right image shows a staining for 
NF200, which labels the myelinated Aβ fibers, with signal confined to the deeper laminae beyond lamina III. 
	  
The nociceptors signal to the spinal cord primarily through the release of the excitatory 
neurotransmitter L-glutamate. Peptidergic nociceptors release in addition substance P and 
CGRP into the synaptic cleft. The postsynaptic glutamate receptors include the ionotropic 
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), kainate and NMDA (N-
methyl-D-aspartate) receptors, and the metabotropic glutamate receptors mGluR1-8 
(Shigemoto et al., 1997; Ugolini et al., 1999). Substance P binds to the G-protein coupled 
neurokinin 1 receptor (NK-1R) (De Felipe et al., 1998) expressed in roughly 80% of spinal 
projection neurons (Todd et al., 2002). CGRP has been described mainly in the context of 
vasodilation when binding to the calcitonin gene-related peptide receptor (CGRPR) in the 
periphery (ter Haar et al., 2010) but it also contributes to spinal pain signaling (Gamse and 
Saria, 1986). Primary nociceptors can activate both excitatory and inhibitory interneurons as 
well as (excitatory) projection neurons directly. Figure 6 shows an example of a direct 
activation of a projection neuron as well as a primary afferent nerve fiber first engaging a 
spinal excitatory interneuron in lamina II that, through the release of glutamate, activates a 
lamina V projection neuron in the spinal cord.  
 
CGRP	  
IB4	  
PKCγ	  
NF200	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Figure 6. Monosynaptic and polysynaptic 
pathways in the dorsal horn of the spinal cord, 
adapted from (Gu and Heft, 2004).  
Primary afferent input can either engage a 
projection neuron in the spinal cord directly as in 
green, or indirectly via an excitatory interneuron as 
in blue. Inhibitory interneurons also exist, and play 
a role in modulating the activity of dorsal horn 
neurons.  
	  
 
Pathological and chronic pain 
It is estimated that 20 % of the European population suffer from pain lasting longer than 6 
months, which is the common definition of chronic pain (Breivik et al., 2006). Sixty percent 
of these patients report that they are at least sometimes unsatisfied with their pain therapy. In 
many cases, the suffering caused by chronic pain is so severe that it leads to depression and 
inability to work. In the USA, the Institute of Medicine states that chronic pain affects about 
100 million adults (about 25%), which is more than those suffering from cancer, diabetes and 
heart disease combined (Scholz and Woolf, 2002). The annual cost to society has been 
estimated at approximately $ 635 billion in medical treatment and loss of productivity. 
General hallmarks of chronic pain syndromes include spontaneous pain felt in the absence of 
sensory stimulation, hyperalgesia (exaggerated pain sensations felt in response to stimuli 
which are already felt as painful under normal conditions) and allodynia (normally innocuous 
stimuli such as light touch or brushing can be felt as painful) (Ringkamp et al., 2013). The 
transition from acute to chronic pain can potentially come from changes occurring at the level 
of the primary afferent fiber, in the spinal cord or come from supraspinal alterations. Chronic 
pain is typically classified as inflammatory pain or neuropathic pain. Both of these pain 
forms differ not only in their initial cause but also in the underlying pathomechanisms. 
Inflammatory pain occurs by definition in the course of chronic inflammation. A typical 
example is rheumatoid arthritis during which immune cells infiltrate the affected joints 
(Neogi and Felson, 2013), and together with cells, such as keratinocytes and mast cells, 
release large amounts of proinflammatory cytokines (Ji et al., 2014). These cytokines do not 
INTRODUCTION 
- 14 - 
only sustain and amplify inflammation but also sensitize nociceptors. Inflammatory pain is in 
fact thought to be to a large extent due to this sensitization of primary nociceptor terminals. 
Important mediators of this sensitization are arachidonic acid metabolites, such as 
prostaglandins, and nerve growth factor that sensitize nociceptors for hours, days or even 
longer. Resident cells, such as keratinocytes and mast cells, also release inflammatory 
mediators, including prostaglandins, protons, ATP, bradykinin, nerve growth factor (NGF) 
and interleukins. A well-known and tangible example of this kind of nociceptor sensitization 
is through NGF, which activates the tyrosine kinase receptor A (TrkA). For instance, during 
inflammation or in a sunburned area of the skin, NGF mRNA is increased in skin cells (such 
as keratinocytes) and the protein is subsequently released from cells locally to active TrkA 
located on nociceptors in the skin (Anand, 1995). TrkA activation initiates several signaling 
cascades involving second messengers. These second messengers in turn activate various 
kinases known to be involved in causing nociceptor hypersensitivity. This combination of 
inflammatory molecules is sometimes referred to as inflammatory soup. Some authors 
classify inflammatory pain and acute pain as “nociceptive pain” because both arise from the 
activation of nociceptors. It should however not be forgotten that inflammation also leads to 
the production to proinflammatory mediators in the central nervous system and that these 
centrally produced mediators cause changes in the central processing of nociceptive stimuli 
(Samad et al., 2002; Neogi and Felson, 2013). In this sense, the mechanisms of chronic 
inflammatory pain differ significantly from those of acute pain. Cellular signaling cascades of 
peripheral nociceptor sensitization are summarized in Figure 7. 
Neuropathic pain originates by definition from a primary damage or dysfunction of the 
somatosensory system (Scadding and Koltzenburg, 2013). Typical causes of neuropathic pain 
include metabolic diseases (diabetes mellitus), injuries (amputations, plexus lesion), 
infections (postherpetic neuralgia, HIV neuropathy), exposures to toxins (ethanol, arsenic, 
thallium etc), and genetic defects. In some patients, the cause of their neuropathic pain 
remains unknown. Neuropathic pain can also originate from damage to central neurons, e.g. 
in patients with brain infarction or spinal cord injury. Important pathomechanisms of 
neuropathic pain include ectopic spontaneous action potential firing in peripheral and central 
neurons of the somatosensory system and the formation of abnormal functional connections 
between neuronal pathways usually processing distinct sensory modalities. It is meanwhile 
well established that peripheral nerve damage induces changes in the central nervous system, 
which also contribute to neuropathic pain. Activation of microglia in response to peripheral 
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nerve damage and subsequent disturbance of chloride homeostasis are meanwhile well-
established mechanisms (Beggs and Salter, 2013).  
 
 
 
Figure 7. Molecules involved in peripheral sensitization (Ji et al., 2014).  
Resident skin cells and infiltrating immune cells locally contribute to the inflammatory soup that sensitizes 
nociceptors. G protein coupled receptors activate kinases, such as protein kinase A and C, phosphoinositide 3-
kinase, calcium/calmodulin-dependent protein kinase, and the mitogen-activated protein kinases (MAPKs) 
extracellular signal-regulated kinase, p38 MAPK and JUN N-terminal kinase. These kinases phosphorylate 
proteins that affect the excitability of the nociceptor, such as sodium channels, transient receptor potential 
family channels and Toll-like receptors.  The result is a heightened sensitivity of the peripheral terminal of the 
sensory fiber to stimuli which cause depolarization, such as modest pressures or temperature differences. 4-
HNE: 4-hydroxynonenal, 5,6-EET: 5,6-epoxyeicosatrienoic acid, FPR1: formyl peptide receptor 1, HETE: 5-
hydroxyeicosatetraenoic acid, HMGB1: high mobility group protein B1, P2X3: P2X purinergic receptor 3, 
PGE2, prostaglandin E2: RTK, receptor tyrosine kinase. 
 
It should however be kept in mind that the distinction between inflammatory and neuropathic 
pain is not always completely strict. Tumor pain and pain in patients with multiple sclerosis 
for example shares characteristics of inflammatory and neuropathic pain (Yousefzadeh et al., 
2015).  
Spinal sensitization 
The processes that cause pain hypersensitivity and persistence can originate not only in the 
periphery but also in the central nervous system. This central sensitization (Woolf, 1983) can 
occur in the spinal cord and in supraspinal centers (Latremoliere and Woolf, 2009). A 
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symptom characteristic of central sensitization is secondary hyperalgesia. This term refers to 
a form of sensitization, which occurs outside an area of inflammation or nociceptor 
activation. It is frequently studied in response to peripheral nociceptor activation by 
intracutaneous capsaicin injection (Magerl et al., 1998). This intracutaneous capsaicin 
injection causes an acute painful sensation through TRPV1 activation at the site of injection 
with an accompanying flare response (reddening of the skin) and a subsequent heat and 
mechanical sensitization at the site of injection. Subsequent to this primary hyperalgesia, an 
area of secondary hyperalgesia occurs with no flare reaction and solely mechanical 
hypersensitivity (Meyer et al., 2006). This secondary hyperalgesia is not accompanied by an 
increased sensitivity of nociceptive fibers but caused by changes in central processing. It is 
believed that pain sensations evoked by mechanical stimulation in the secondary hyperalgesic 
area are elicited by activation of low threshold mechanosensitive fibers. A large body of 
evidence indicates that central sensitization also occurs in many clinically relevant chronic 
pain conditions.  
Activity dependent forms of central sensitization 
Intense nociceptive input to the spinal cord can induce long-lasting pain sensitization in the 
absence of inflammation or neuropathy. The underlying cellular and synaptic processes 
probably include an increase in excitability of spinal cord neurons or diminished inhibitory 
pain control in the spinal cord (Woolf, 1983). 
Increased synaptic excitation 
Intense C fiber input to lamina I projection neurons induces a form of synaptic plasticity 
which is remarkably similar to long-term potentiation (LTP) in the hippocampus (Sandkühler 
et al., 1997). Hippocampal LTP has first been described by Terje Lømo in 1966 (Bliss and 
Lømo, 1966) and is thought to be a cellular and synaptic correlate of learning and memory 
formation. In the spinal cord dorsal horn, LTP may contribute to exaggerated pain sensations 
(in particular hyperalgesia) following injury or inflammation. 
Dorsal horn LTP can be experimentally induced in lamina I projection neurons at nociceptive 
synapses expressing NK-1R by intense C fiber stimulation (Ikeda et al., 2003). This spinal 
LTP is abolished by blockade of NK-1R, NMDA receptors or low threshold voltage-gated 
calcium channels (Ikeda et al., 2006). Depending on the type of projection neuron 
(parabrachial or periaqueductal grey) LTP required either high or low stimulation 
frequencies. Recent work by Bonin & De Koninck confirmed the remarkable similarities 
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between spinal pain sensitization process and hippocampal memory formation through LTP 
(Bonin and De Koninck, 2014). Spinal LTP observed after intraplantar capsaicin injection 
and, like hippocampal LTP, depends on protein synthesis and has the potential to be 
extinguished if re-activated (by a second capsaicin injection) paired with protein synthesis 
inhibition. 
Diminished synaptic inhibition 
Well-balanced excitation and inhibition in the spinal nociceptive circuits is necessary to 
preserve their physiological functions and to keep them quiescent during innocuous inputs. 
The inhibitory interneurons rely on their release of GABA and glycine to evoke inhibition of 
the postsynaptic cells, which express ionotropic GABAA and strychnine-sensitive glycine 
receptors. Through the central pore of the activated GABAA and glycine receptors, negatively 
charged Cl- ions flow through the cell membrane and reduce neuronal excitation through 
hyperpolarization and activation of a shunting conductance.  
The first experiments implicating a GABAergic or glycinergic tone modulating nociceptive 
processes at the level of the spinal cord were performed by spinal application of the glycine 
receptor antagonist strychnine at sub-convulsive concentrations in rats (Beyer et al., 1985). 
These rats exhibited reoccurring grooming, biting and licking behavior as well as 
vocalization responses to light cutaneous stimulation. Similar results were obtained after 
spinal application of the GABAA receptor antagonist bicuculline (Sivilotti and Woolf, 1994). 
Subsequent studies could show that strychnine and bicuculline exaggerate the pain sensitivity 
seen in rats after sciatic nerve constriction (Yamamoto and Yaksh, 1993). A recent 
publication demonstrates that targeted unilateral silencing or ablation of dorsal horn 
glycinergic interneurons evoked thermal and mechanical hyperalgesia as well as signs of 
spontaneous discomfort (Foster et al., 2015). 
On the cellular level, loss of GABAergic inhibition in the dorsal horn causes Aβ fiber input 
to excite spinal nociceptive neurons. Activity of lamina II neurons was recorded before and 
after an application of the GABAA receptor antagonist bicuculline (Figure 8). Under control 
condition, Aβ fiber intensity had only minor effects, while in the presence of bicuculline, Aβ 
fiber stimulation elicited hyperexcitability (Baba et al., 2003). This suggests that loss of 
GABAergic inhibition in the spinal cord can turn normally innocuous stimuli into painful 
stimuli. Similar observations can be made after block of inhibitory glycine receptors (Sivilotti 
and Woolf, 1994).  
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Figure 8. Aβ fiber stimulation in the absence 
(control) and presence of bicuculline, modified 
from (Baba et al., 2003).  
Electrophysiological patch clamp recordings from 
lamina II of lumbosacral rat spinal cords. 
Stimulation of the dorsal root at Aβ fiber intensity 
usually evokes fast mono- or polysynaptic 
excitatory postsynaptic currents with short duration 
(50–200 ms, se control traces). After 40 µM bath 
application of bicuculline, Aβ fiber intensity 
stimulation reproducibly causes long-lasting (300–
1000 ms) polysynaptic excitatory postsynaptic 
currents. 
Research from the last 15 years has shown that GABAergic and glycinergic inhibition can get 
compromised through a variety of different mechanisms including posttranslational changes 
in neurotransmitter receptor function, regulation of neurotransmitter synthesis and changes in 
the intracellular concentration of chloride (Zeilhofer et al., 2009).	  
The inflammatory mediator prostaglandin PGE2 – but not the prostaglandins PGI2, PGF2α or 
PGD2 – causes disinhibition in spinal dorsal horn neurons (Ahmadi et al., 2002) through 
reduced responsiveness of superficial dorsal horn glycine receptors, which occurs through a 
PGE2- and EP2 receptor-dependent activation of protein kinase (PK) A acting on the glycine 
receptor subunit α3 (Figure 9). Mice lacking this subunit show reduced sensitization by spinal 
PGE2 application or  by peripheral inflammation (Harvey et al., 2004). 
	  
Figure 9. Spinal expression pattern of α3 glycine receptors and modulation by PGE2 from (Harvey et al., 
2004) and (Ahmadi et al., 2002).  
Recordings are from superficial rat dorsal horn neurons. Top shows recordings from untreated rat lumbar spinal 
cord slices. Bottom shows recording during treatment with PGE2, which leads to a reduction in mIPSC 
amplitude but not frequency. 
	  	  	  	  	  control	  
bicuculline	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Following peripheral nerve injury, the potassium chloride co-exporter 2 (KCC2) is down-
regulated in a process that is dependent on brain derived neurotrophic factor (BDNF) released 
from activated (ATP-stimulated) microglia (Coull et al., 2005) (Figure 10). This KCC2 
down-regulation causes a disruption of the transmembrane chloride gradient in superficial 
dorsal horn neurons. This ensuing hyperalgesia that can be mimicked in healthy animals by 
spinal application of KCC2 blockers or silencing KCC2 RNA (Coull et al., 2003). 
	  
Figure 10. GABA becomes depolarizing in the presence of ATP-stimulated microglia, modified from 
(Coull et al., 2005).  
Left shows lamina I neurons from control mice without ATP-stimulated microglia (Microglia – ATP) exhibiting 
a hyperpolarizing effect of GABA application on the cellular voltage at resting membrane potentials. Same 
experiment repeated with ATP-stimulated microglia shows a depolarizing effect of GABA application at resting 
membrane potentials. 
In 2011, Zhang et al. showed that epigenetics are implicated in chronic pain. During 
inflammation and nerve injury, the GABA synthesizing enzyme GAD65 is down-regulated in 
the brainstem by epigenetic changes (Zhang et al., 2011). The histone deacetylase (HDAC)-
mediated histone hypoacetylation suppressed the expression of the gene Gad2, encoding the 
protein GAD65, leading to disinhibition in the nucleus raphe magnus. HDAC inhibitors were 
effective in reversing the hyperalgesia. A down-regulation of GAD65 has also been reported 
for the spinal cord (Moore et al., 2002; Lorenzo et al., 2014).  
Structural changes 
In addition to the function changes described above, structural changes in dorsal horn circuits 
have also been proposed to contribute to pain sensitization. Inflammation induced by 
peripheral injection of complete Freund’s causes Aβ fibers to sprout into the superficial 
laminae of the spinal cord (Ma and Tian, 2002). As a result, innocuous stimulation would 
activate superficial nociceptive dorsal horn neurons. The extent to which this plasticity 
contributes to chronic pain is controversial. Recent reports have not found Aβ fiber sprouting 
to occur in spite of observable allodynia, for instance after nerve injury (Hughes et al., 2003; 
Shehab et al., 2004).  
Peripheral nerve damage may also induce the death of dorsal horn inhibitory interneurons 
(Moore et al., 2002; Scholz et al., 2005; Meisner et al., 2010), but others have provided data 
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suggesting that cell death in the dorsal horn is not required for the development of 
neuropathic hyperalgesia (Polgár et al., 2004; Polgár et al., 2005; Todd, 2010). 
Supraspinal pain processing 
From the spinal cord, neurons project up towards the brain along several different ascending 
tracts (Figure 11). These include the spinothalamic, spinoreticular, spinoparabrachial, 
spinomesencephalic, spinoolivary, spinohypothalamic, spinoamygdalar and spinocerebellar 
pathways (Mai and Paxinos, 2012). The most prominent ones are the spinothalamic tract 
(projecting to the thalamus) and the spinoreticular tract (projecting to the brainstem). These 
various projections together make up the three dimensions of pain sensation that were 
suggested by Melzack and Casey in 1968 (Melzack and Casey, 1968): 
 sensory-discriminative: sensing the intensity, location, quality and duration of the pain, 
involving the brain areas thalamus, primary and secondary somatosensory cortex 
(Auvray et al., 2010) 
 affective-motivational: unpleasantness and urge to escape the unpleasantness of the pain, 
involving brain areas such as anterior cingulate cortex and amygdala (Gao et al., 2004) 
 cognitive-evaluative: cognitions such as appraisal, evaluation of pain, cultural values, 
distraction and hypnotic suggestion of the pain, with activity seen during fMRI even in 
absence of painful stimuli during evaluation tasks in insular and prefrontal cortex (Kong 
et al., 2006) 
Melzack and Casey predicted that the experience of pain is not only described by its intensity 
or magnitude of stimulation, but also is influenced by psychological factors and the 
environmental context (Geva and Defrin, 2013; Petersen et al., 2014).  
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Figure 11. The neuroaxis of pain and its various relay stations on the way up to the brain, from (Basbaum 
et al., 2009).  
A “painful” peripheral stimulus activates the primary afferent nerve fiber (nociceptor) which terminates in the 
dorsal horn of the spinal cord. The termination is a chemical synapse within which glutamate is released to 
activate the postsynaptic spinal neuron. In this monosynaptic example, the postsynaptic neuron is a projection 
neuron. The axon of the projection neuron crosses the midline and proceeds rostrally up to the brain along the 
spinothalamic, spinoreticular or spinoparabrachial pathway – although spinal projections to other areas of the 
brain also occur. In the example of the thalamus, the spinothalamic axons forms another chemical synapse, 
where the postsynaptic target is a thalamic neuron that projects to many higher centers in the brain, such as the 
primary and secondary sensory cortex or anterior cingulate gyrus and cingulate cortex. Not only does the spinal 
cord serve as a runway for ascending pain information, but also descending pain inhibition. From the brainstem 
nucleus rostroventromedial medulla and periaqueductal grey, fibers descend back down to the dorsal horn to 
inhibition pain transmission form reaching the brain. 
 
Descending modulation of dorsal horn pain processing 
Different descending fibers from the brain onto the dorsal horn of the spinal cord have the 
capacity to either increase and decrease spinal nociception (Gebhart, 2004). This top-down 
modulation is mainly mediated by descending monoaminergic pathways from various 
supraspinal sites that either inhibit or facilitate transmission of nociceptive information at the 
level of the dorsal horn (Millan, 2002) (see Figure 12). 
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Figure 12. Descending modulation of pain, from (Benarroch, 2008) and (Millan, 2002).  
(A) Descending monoaminergic pathways. (B) Overview of described molecules involved in descending 
inhibition (DI) and facilitation (DF) acting directly or indirectly on dorsal horn neurons. At the dorsal horn, 
pathways mediating DI and DF have opposite effects on primary afferent fiber (PAF) terminals, projection 
neurons (PN), inhibitory interneurons (ININ) and excitatory interneurons (EXIN). DRG, dorsal root ganglion; 
NO, nitric oxide; CCK, cholecystokinin; NT, neurotensin; GLU, glutamate; NMDA, N-methyl-d-aspartate; 
ACh, acetylcholine; musc, muscarinic; nic, nicotinic; DYN, dynorphin; ENK, enkephalin; β-EP, β-endorphin; 
EM, endomorphin; GABA, γ-hydroxy-butyric acid; Hist, histamine; CB, cannabinoid; NA, noradrenaline; SP, 
substance P; NPVF, neuropeptide VF and OFQ, orphanin FQ (nociceptin)  
The periaqueductal grey (PAG) has been recognized for over half a century for its ability to 
cause analgesia after being electrically stimulated (Reynolds, 1969). Subsequent studies 
revealed the ventrolateral PAG as the main projection area responsible for analgesia through 
descending inhibition (Yaksh and Rudy, 1978). More recently, it was discovered that 
stimulation in many sites upstream of the PAG in the brain, including the somatosensory 
cortex, hypothalamus, thalamus, as well as midbrain, pons and medulla structures could 
produce inhibitory effects on spinal nociceptive processing (Gebhart, 1986; Hammond, 
1986). A particularly important relay station downstream of the PAG was shown to be the 
rostroventromedial medulla (RVM). Antinociception seen after PAG-stimulation could be 
abolished when the RVM was inactivated by local injection of the sodium channel blocker 
lidocaine (Gebhart et al., 1983). Today, many more descending pathways have been 
described, involving the cannabinoid and opioid system. 
Thalamus,	  
Hypothalamus	  
A	   B	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Supraspinal pain sensitization 
The spinal activity-dependent LTP or long term depression (LTD) can also manifest through 
prolonged activity reaching the supraspinal pain processing sites. The consequences can 
similarly be a dysfunctional and hyperexcitable pain circuit and can potentially explain the 
various comorbidities often seen in patients suffering from chronic pain, such as anxiety and 
depression (Yalcin et al., 2014). Epidemiological studies reveal that around 50% of chronic 
pain patients also suffer from depressive disorders (Kroenke et al., 2011). 
Likely, different brain regions will be involved in supraspinal sensitization, depending on the 
type of pain disorder. Anatomically, the brain is more complex than the spinal cord and 
molecular changes in one nucleus can affect associated brain regions that together cause a 
persistent pain state. A time-dependent increase in descending facilitation from the RVM 
have been shown to maintain neuropathic pain states (Burgess et al., 2002). After spinal 
nerve ligation, lidocaine injected into the RVM reverses thermal hypersensitivity one week 
after nerve injury, but is ineffective three days after injury. The authors also found that 
lesioning the descending dorsolateral funiculus prevented the supraspinally-induced increase 
of dynorphin after spared nerve injury, and also blocked maintenance of the hyperalgesia. 
Excitatory descending input to the spinal cord is mediated by serotonin released from 
brainstem neurons (Suzuki and Dickenson, 2005). Reports have shown that ondasterone, the 
antagonist of 5HT3 receptors, has efficacy against mechanical pain after peripheral nerve 
injury (Suzuki and Dickenson, 2005). A study on human patients with chronic neuropathic 
pain showed that block of 5HT3 receptors with ondasterone could significantly reduce pain 
scores compared to placebo (McCleane et al., 2003). Post-stroke pain is a form of untreatable 
pain that develops after a brain stroke episode. Although poorly understood, animal models 
such as that of experimental thalamic hemorrhage by unilateral intra-thalamic collagenase IV 
injection have helped to describe its features (Yang et al., 2014). 
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CURRENTLY AVAILABLE ANALGESICS 
Several classes of analgesics are available today with distinct modes of action and clinical 
indications. These compounds mainly fall into two categories, cyclooxygenase (COX) 
inhibitors and opioids. Some forms of chronic pain, in particular neuropathic pain respond 
better to anticonvulsants or antidepressants than to classical analgesics. 
Non-steroidal anti-inflammatory drugs (NSAIDs) 
Non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen and naproxen, 
inhibit the cyclooxygenase enzymes (COX-1 and COX-2) that convert arachidonic acid into 
prostaglandin precursors. Prostaglandins serve important functions in body homeostasis but 
are also mediators of pain and inflammation. COX-2 expression is induced in many tissues 
by pro-inflammatory cytokines and leads to subsequent increases in tissue levels of 
prostaglandins to further promote inflammation, to sensitize peripheral nociceptors and spinal 
nociceptive processing, and to induce fever through a hypothalamic site. Inhibition of 
prostaglanin synthesis by NSAIDs therefore reduces inflammatory hyperalgesia and fever 
and dampens symptoms of inflammation (Day and Graham, 2013). Prostaglandins involved 
in body homeostasis originate mainly from COX-1. Typical side-effects of classical non-
selective COX-1/2 inhibitors include gastric ulcer formation and kidney damage. The more 
recently developed COX-2 selective inhibitors such as celecoxib, etoricoxib and rofecoxib 
(the latter has been withdrawn from the market in 2004) have shown analgesic efficacy with 
reduced risk of gastric bleeding (Derry and Moore, 2013). Both non-selective NSAIDs and 
COX inhibitors increase the risk of cardiovascular events. Paracetamol is a mild analgesic 
with fever reducing properties but no anti-inflammatory action. Several mechanisms of action 
have been suggested, including COX-2 inhibition (Hinz et al., 2008) and cannabinoid 
receptor modulation (Högestätt et al., 2005). Paracetamol causes fewer side effects but an 
overdose can be lethal due to liver toxicity. While commonly used for treatment of mild and 
inflammatory pain, these drugs are not effective in pain disorders that manifest independently 
of prostaglandin production, such as neuropathic pain.  
Opioids 
Opioids (such as morphine) are agonists at opioid receptors, which are G protein coupled 
receptors that, in general, lead to inhibition of synaptic transmission and neuronal 
excitability. In the pain pathways, opioids have two major sites of action. In the spinal dorsal 
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horn, they inhibit the release of excitatory neurotransmitters from primary nociceptor 
terminals in the spinal cord. In the brain stem, opioids enhance the activity of endogenous 
pain control by disinhibiting antinociceptive fiber tracts that descend form the brainstem to 
the dorsal horn.  
Opioids are highly efficacious analgesics but exhibit various side-effects such as sedation, 
constipation, respiratory depression, strong euphoria, opioid dependence, chronic itch 
(pruritus), addiction and the paradoxical opioid-induced hyperalgesia. Prolonged use also 
induces tolerance (i.e. a progressive loss of effect during prolonged treatment) through only 
incompletely understood mechanisms (Pradhan et al., 2010). Opioids are excellent drugs for 
the treatment of acute (traumatic or postoperative) pain and chronic malignant pain. 
However, their use in patients with chronic non-malignant pain is problematic mainly 
because of their propensity to dependence (Hermann et al., 2005). Furthermore, their efficacy 
in neuropathic pain patients remains controversial (McNicol et al., 2013).  
Anticonvulsants and antidepressants 
Compounds used to treat nervous system disorders unrelated to pain have in some cases 
therapeutic potential for the treatment of chronic pain. In case of neuropathic pain, such 
compounds include mainly antidepressants and anticonvulsants.  
Antidepressants have shown potential in the treatment of various persistent pain states, 
including neuropathic pain, fibromyalgia, rheumatoid arthritis, low back pain and headache 
(Dharmshaktu et al., 2012). Drugs approved for use in at least some neuropathic pain 
conditions include the tricyclic antidepressant amitriptyline. Its mood-altering properties 
originate most likely from the inhibition of serotonin and noradrenaline reuptake. A 
prolonged presence of noradrenaline and serotonin in spinal cord synapses probably also 
underlies the efficacy of amitriptyline in neuropathic pain. More recently developed 
serotonergic and adrenergic antidepressants, such as duloxetine (a selective noradrenaline-
serotonin reuptake inhibitor, SSNRI), are also well established in the treatment of 
neuropathic pain (Bril et al., 2011) and cause fewer side-effects. 
Anticonvulsants and antiepileptic drugs have also shown to be effective against chronic pain, 
including fibromyalgia, diabetic neuropathy and neuropathic pain (Attal et al., 2010; Moore 
et al., 2011). Gabapentin and pregabalin are first-line treatments against neuropathic pain. 
They probably reduce pathologically heightened nociceptive transmission at the primary 
INTRODUCTION 
- 26 - 
nociceptor terminal by targeting the α2δ subunit of voltage gated calcium channels 
(Silverman, 2008; Celikyurt et al., 2011). While their names contain GABA, it should be 
noted that neither gabapentin nor pregabalin bind to GABAA or GABAB receptors.  
Carbamazepine, a voltage gated sodium channel blocker (Hebeisen et al., 2015), is an 
anticonvulsant, mood-stabilizer as well as analgesic effective for trigeminal neuralgia and 
neuropathic pain, but is not recommended as a first choice analgesic due to increased risk of 
suicide 9=UH=?lAP=H	.	  
	  
TESTS FOR MEASURING PAIN IN LABORATORY ANIMALS 
As stated above, pain is defined by the IASP as a conscious sensation. Because animals 
cannot report their pain as humans can do, pain studies in animals have to rely on the 
assessment of surrogate parameters. Almost all pain tests in animals are based on the 
quantification behavioral (motor) read-outs. These include withdrawal responses upon 
exposure to acute noxious stimulation or spontaneous aversive behaviors, such as flinches of 
irritated paws and vocalizations, and read-outs related to conditioned place preference or 
aversion. Read-outs independent of motor function are mainly based on imaging or EEG 
techniques measuring brain activity.  
Tests designed to measure pain in rodents 
Withdrawal response-based measurement 
Acute nociceptive pain sensitivity is often quantified according to the threshold intensity of a 
nociceptive stimulus that evokes a response or according to the response latency, i.e. the time 
interval between the onset of a defined nociceptive stimulus and the onset of the animal’s 
response (Le Bars et al., 2001; Barrot, 2012). Nociceptive stimuli applied in such tests 
include electrical, chemical, thermal and mechanical stimuli.  
Pain induced by electrical application is less commonly used in animal pain tests, mainly as it 
involves activation of all primary afferents and does not represent a naturally occurring 
stimulus (Barrot, 2012). The readouts are escape behavior or vocalization of the animal. 
Electrical pain tests are often used in human studies due to the stimuli being non-invasive and 
its parameters relatively easily controlled. 
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Sensitivity to heat can be assessed in the hot plate test (van Eick, 1967), where a mouse is 
placed in an enclosed chamber with the floor at temperatures of 40-50°C and the latency to 
respond, either by licking of the hind paws or jumping of the animal, is recorded. The 
Hargreaves test allows for repeated measurements by focusing a warm beam of light from 
below the animal, placed on a glass surface, directed to the hindpaw or tail and measuring 
latency to withdrawal (Hargreaves et al., 1988). Cold sensitivity is assessed either by 
injection of a compound that induces a cold sensation, such as icillin (Tse and Wei, 1986), or 
by application of a drop of acetone to the plantar surface of the hind paw (Kontinen et al., 
1998). A recent publication describes the use of dry ice applied to a glass surface below the 
hind paw as a means to test for cold allodynia (Brenner et al., 2012).  
Mechanical stimulation is most often applied from below onto the plantar surface of the hind 
paw of an animal situated on a metal mesh. Noxious mechanical stimulation is performed 
with the pin prick test, where a sharp needle that does not perforate the skin is applied to the 
hind paw and percentage of elicited flinching responses are calculated (Krag and Rasmussen, 
1975). The Randall-Selitto apparatus allows clamping the hind paw or tail with manually 
controlled pressure intensity, but requires the animal to be restrained or trained prior to 
testing (Randall and Selitto, 1957). Non-noxious stimuli include the flexible von Frey 
filaments, designed over 100 years ago by Austrian-German physiologist Maximilian von 
Frey (Norrsell et al., 1999). Early pain tests relied on a set of calibrated filaments that applied 
defined pressures to the tissue, depending on the rigidity of the filament. Later, the handheld 
electronic von Frey apparatus allowed for using a single flexible filament for exact readouts 
of the pressure applied that had been applied manually (Vivancos et al., 2004). The latest 
dynamic von Frey applies pressure with a defined speed and acceleration and records paw 
withdrawal threshold automatically (Nirogi et al., 2012).  
Tests involving on-going nociceptive behavior 
A limitation of the tests discussed above is that they do not evaluate spontaneous responses to 
ongoing pain, and rely on readouts that, in most cases, involve spinal reflexes rather than 
supraspinal pain processing. Chemical nociception is assessed by injection of for instance 
capsaicin (Baraz et al., 1968), mustard oil (Wesselmann et al., 1998) or formalin (Hitchens et 
al., 1967), which are most often injected subcutaneously into the plantar surface of the hind 
paw or the tail. The subsequent readout is the amount of time spent or the number of 
instances of licking, biting or flinching of the injected tissue. Visceral pain is assessed by 
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intraperitoneal injection of acetic acid (Koster et al., 1959) or hypertonic saline (Collier and 
Schneider, 1969), whereafter the number of body writhing events is counted . 
More recently developed alternative approaches include the facial grimace scale test, which 
allows a partly automated assessments of spontaneous pain by studying the facial expression 
of animals in pain (Sotocinal et al., 2011). The tests involve video recordings of the animals 
and off-line analysis of several parameters such as orbital tightening, nose and cheek 
flattening, changes in ear shape, and abnormal whisker orientation. Rodents in pain will also 
spontaneously give off ultrasound vocalizations above 20 kHz. Although reproducibly 
recording pain-induced ultrasound vocalizations of animals over long periods of time has 
proven a challenging (Wallace et al., 2005), robust readouts for up to several week have been 
obtained for both cancer pain and neuropathic pain when 37 and 50 kHz vocalizations were 
recorded (Kurejova et al., 2010).  
Conditioned place preference 
Another approach has been to use place preference (or place conditioning) tests as a means to 
quantify the analgesic properties of drugs (King et al., 2009; Stevenson et al., 2015). In this 
paradigm, rodents with chronic pain are placed in a cage with two identical compartments 
connected to each other. Naïve animals will spend equal times exploring both chambers. To 
assess analgesic activity of a test compound, animals in chronic on-going pain conditions will 
be “conditioned”, i.e. they will be trained to associate one of the two compartments with pain 
relief. This is done by repeatedly treating the animal with an analgesic drug in one of the 
chambers. After this training session a conditioned animal will prefer the chamber associated 
with drug treatment over the other chamber. In this way, potential pain relieving efficacy can 
be studied based on reduction in tonic pain rather than stimuli-induced responses. An 
important limitation of the test is that it will produce false positive results for drugs with 
rewarding properties (Navratilova et al., 2013). 
Functional brain imaging 
As outlined above, pain is defined as a “conscious sensation” and must as such have a 
cellular correlate in neuronal activity measureable in the cerebral cortex or related brain 
structures (Apkarian et al., 2013). Functional brain imaging employing the so called blood 
oxygen level-dependent (BOLD) effects should hence be well-suited to capture the very 
essence of pain (Lassen et al., 1978). BOLD effect-based imaging of brain activity has 
become a core technique in human pain research. Seminal studies have led to the view that in 
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the brain pain is not represented in a single area but rather leads to the activation of several 
brain areas potentially representing the different aspects of pain (sensory versus affective etc) 
(Kenshalo and Isensee, 1983). These areas have collectively been called the “pain matrix” 
(Derbyshire et al., 1997). More recent studies have challenged this view showing that very 
similar brain areas can be activated by different arousing stimuli unrelated to pain (salience 
detection) (Legrain et al., 2011). Most recent evidence indicates that activation of parts of the 
insular cortex might be most closely related to the experience of pain (Barthas et al., 2015).  
fMRI is also used to assess pain in laboratory animals but its use in preclinical pain research 
is less wide-spread than in human pain research. Nevertheless, pain imaging has been used to 
assess analgesic activity objectively in rodents. Figure 13 shows an example of a study in 
which rat fMRI was used to assess the analgesic activity of a novel benzodiazepine site 
ligand.   
	  
Figure 13. fMRI scans of inflamed rats at the thalamic level, treated with vehicle or 1mg/kg of L-838,417.  
BOLD signal in vehicle (left brain) and drug (right brain) treated rats. Key brain regions active during pain 
sensation had reduced BOLD signal after treatment with L-838,417. MTh, medial thalamus; S1, primary 
somatosensory cortex; Cg, cingulate cortex; I, insular cortex; LS, limbic system; HT, hypothalamus; HL, 
representation of hindlimb in S1. Left, left hemisphere. 
 
Models of chronic pain  
The majority of chronic pain models involve partial damage to peripheral nerves. The first 
among those was the chronic constriction injury (CCI) model (Bennett and Xie, 1988), in 
which several loose ligatures are placed around a peripheral nerve, typically the sciatic nerve. 
This procedure interferes with the blood supply of the nerve and causes progressive damage 
of the affected nerve fibers followed by the development of heat, cold and mechanical 
hyperalgesia over several days. This hypersensitivity persists for several weeks. Other more 
recently developed models include the spared nerve injury (SNI) (Decosterd and Woolf, 
2000), spinal nerve ligation (SNL) (Kim and Chung, 1992), spinal nerve transection (SNT) 
INTRODUCTION 
- 30 - 
(Sheen and Chung, 1993), and partial sciatic nerve injury (PSNI) (Seltzer et al., 1990), 
summarized in Figure 14. Animals subjected to these surgeries recapitulate many of the 
symptoms observed in humans, such as touch-evoked allodynia, and thermal and mechanical 
hyperalgesia (Honoré et al., 2011). These neuropathic pain models produce a hypersensitivity 
lasting for several weeks. 
 
	  
Figure 14. Surgical protocols for eliciting models of chronic neuropathic pain in rodents, from (Honoré et 
al., 2011). 
Inflammatory pain is typically studied after injection of pro-inflammatory compounds into 
one paw. Frequently used compounds include the yeast β-glucan zymosan A (Doherty et al., 
1985), the seaweed polysaccharide carrageenan (Rios and Jacob, 1983), and Complete or 
Incomplete Freund’s Adjuvant (Yonehara et al., 1983). 
Other models are aimed to recapitulate specific painful pathologies. Intravenous injection of 
streptozotocin causes diabetes and evokes a painful diabetic neuropathy within one week of 
injection, including thermal hyperalgesia (Forman et al., 1986). Paclitaxel (taxol) is a 
cytotoxic agent used in chemotherapy of different cancers. When given systemically to 
rodents, it causes a peripheral painful neuropathy. Cancer pain can be studied in rodents by 
carcinoma cell transplants injected into various bones of the hind limb (most often used are 
femur, tibia and calcaneus) (Medhurst et al., 2002). The animals typically develop bone-
tumor and ensuing structural damage of the affected bone, accompanied with mechanical 
hyperalgesia within two weeks of transplantation.  
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The following chapter provides a comprehensive overview of the current knowledge on 
GABAA receptors in spinal pain control and on their potential role as targets for novel 
analgesic compounds. 
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Abstract  
GABAA receptors (GABAARs) and glycine receptors (GlyRs) are key elements of the spinal 
control of nociception and pain. Compromised functioning of these two transmitter systems 
contributes to chronic pain states. Restoring their proper function through positive allosteric 
modulators should constitute a rational approach to the treatment of chronic pain syndromes 
involving diminished inhibitory spinal pain control. Although classical benzodiazepines (i.e. 
full agonists at the benzodiazepine binding site of GABAARs) potentiate synaptic inhibition 
in spinal pain controlling circuits, they lack clinically relevant analgesic activity in humans. 
Recent data obtained from experiments in GABAAR point-mutated mice suggests dose-
limiting sedative effects of classical non-specific benzodiazepines as the underlying cause. 
Experiments in genetically engineered mice resistant to the sedative effects of classical 
benzodiazepines and studies with novel less sedating benzodiazepines have however shown 
that profound antihyperalgesia can be obtained at least in preclinical pain models. Present 
evidence suggests that compounds with high intrinsic activity at α2-GABAAR and minimal 
agonistic activity at α1-GABAAR should be pursued in order to achieve maximum 
antihyperalgesia and no unwanted sedation. On-going preclinical studies in genetically 
engineered mice and clinical trials with more selective benzodiazepine site agonists should 
soon provide additional insights into this emerging topic. 
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Introduction 
Chronic pain is a severe medical condition affecting millions of patients world-wide. It is 
almost generally accepted that neuronal and synaptic plasticity occurring at different levels of 
the neuraxis are major contributors to chronic pain (Luo et al., 2014; Sandkühler, 2009; 
Zeilhofer et al., 2009b) (for a schematic illustration of the pain pathway see figure1). Some of 
these neuroplastic changes occur already in the peripheral terminals of nociceptors, which 
sense noxious stimuli arriving at the skin or in other peripheral tissues and convey them to 
the central nervous system. The central terminals of these nociceptors innervate the substantia 
gelatinosa (lamina II) spinal dorsal horn, or the trigeminal nucleus of the brainstem in case of 
those nociceptors coming from the facial skin or the meninges.  
 
 
 
 
 
Figure 1. Schematic description of ascending 
pain pathways and descending anti-
nociceptive fiber tracts.  
Nociceptive (“painful”) signals are conveyed by 
sensory fibers whose cell bodies reside in the 
dorsal root ganglia (DRGs). They reach the 
CNS at the level of the spinal dorsal horn (DH), 
where nociceptor terminals release glutamate to 
excite postsynaptic second order neurons. These 
central neurons transmit the nociceptive 
information via the brainstem and the midbrain 
to cortical areas, where the conscious sensation 
of pain arises. Descending antinociceptive 
pathways are controlled by cortical areas, which 
contact the hypothalamus (HT) and the 
periaqueductal grey (PAG). The PAG in turn 
controls the rostral ventromedial medulla 
(RVM), which constitutes the main origin of 
descending antinociceptive fibers innervating 
the spinal cord.  
 
 
 
From there, signals are propagated through various relay stations in the brainstem, midbrain 
and thalamus to several cortical areas which give rise to the conscious sensation of pain. One 
site that has attracted particular attention in pain-related neuroplasticity is the spinal dorsal 
horn, which constitutes as the first site of synaptic integration in the pain pathway. Neurons 
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located in the spinal dorsal horn integrate primary afferent sensory signals of painful and 
non-painful modalities with input from descending fiber tracts, which can either inhibit or 
facilitate pain. Inhibitory interneurons have been attributed a critical role in this process 
already in the gate-control-theory of pain (figure 2, Melzack & Wall, 1965). 
 
 
Figure 2. Gate-control theory of pain (Wall 
& Melzack, 1969).  
Inhibitory neurons located in the substantia 
gelatinosa (SG) control the spinal pain gate. 
According to the original concept these 
neurons were controlled by non-nociceptive 
input from mechanosensitive fibers and by 
nociceptive input in opposite directions. Their 
activation would in turn control the spinal out-
put system (T).  
 
Although some of the synaptic connections proposed in the original scheme do apparently 
not exist, plenty of evidence indicates that compromising the function of inhibitory dorsal 
horn neurons induces symptoms reminiscent of chronic pain syndromes in humans. Animals 
develop an exaggerated sensitivity to painful stimuli (hyperalgesia), they respond with 
withdrawal responses upon exposure to stimuli, which are normally not felt as painful 
(allodynia), and they also show signs of spontaneous discomfort. Many lines of evidence 
indicate that typical causes of chronic pain such as inflammation or neuropathies compromise 
the function of inhibitory interneurons in the spinal dorsal horn through different mechanisms 
(for a review see Zeilhofer et al.,  2012a). According to this concept, a facilitation of 
inhibitory neurotransmission should be a rational strategy for the treatment of many chronic 
pain states. Yet so far, none of the established analgesics acts through a facilitation of 
inhibitory neurotransmission. In the following text, we will review mechanisms of pain-
related spinal disinhibition and evidence supporting the concept that novel subtype-selective 
benzodiazepine agonists would be suitable for the treatment of chronic pain syndromes. In 
the context of this review, we use the term “benzodiazepine” for all agonists at the 
benzodiazepine binding site of GABAARs independent of their chemical structure. It should 
also be mentioned here that GABAARs exist, which are resistant to modulation by classical 
benzodiazepines. These receptors contain α4 or α6 subunits instead of α1, α2, α3, or α5, or 
a γ1 or δ subunit instead of the γ2 subunit. These benzodiazepine-insensitive receptors are 
quite abundant in several brain regions (e.g. thalamus and cerebellum), but their expression in 
the spinal cord is very sparse.  
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Synaptic disinhibition in pathological pain 
Fast synaptic inhibition in the spinal dorsal horn is mediated by GABA and glycine acting 
respectively at GABAAR and strychnine-sensitive GlyRs. Plenty of evidence indicates that 
blockade of spinal GABAARs or GlyRs produces signs of allodynia and spontaneous pain 
(Beyer et al., 1985; Miraucourt et al., 2007; Roberts et al., 1986). More recent studies 
provided insights into the mechanism of this sensitization on the level of dorsal horn neuronal 
circuits. The most consistent observation in these studies was a strong increase in 
polysynaptic input onto lamina II neurons after application of the GABAAR antagonist 
bicuculline (Baba et al., 2003). A second finding was related to the synaptic input of lamina I 
projection neurons, which express the neurokinin 1 (NK1) receptor. These neurons serve an 
essential role in the relay of pathological pain, as their ablation strongly reduces hyperalgesia 
induced by inflammation and neuropathy (Nichols et al., 1999). Under normal conditions, 
these neurons receive sensory input almost exclusively from nociceptors (C and Aδ fibers). 
Blockade of GABAA and GlyRs however led to the de novo appearance polysynaptic 
responses from Aβ fibers (Torsney & MacDermott, 2006). These newly appearing 
polysynaptic connections likely underlie the allodynia seen in vivo after spinal application of 
bicuculline or strychnine. An increase in polysynaptic Aβ fiber input onto substantia 
gelatinosa (lamina II) may also occur as an endogenous process in chronic pain states (Baba 
et al., 1999).  
Several groups have identified signaling pathways that reduce inhibitory synaptic 
transmission in inflammatory or neuropathic pain states (figure 3). A prostaglandin E2-
mediated phosphorylation of superficial dorsal horn GlyRs renders these receptors less 
responsive to glycine (Ahmadi et al., 2002; Harvey et al., 2004; Reinold et al., 2005). 
Peripheral nerve damage leads to a down-regulation of the GABA synthesizing enzyme 
GAD65 in the spinal cord (Moore et al., 2002), and both inflammation and nerve injury cause 
an epigenetic down-regulation of the same enzyme in the brainstem (Zhang et al., 2011). A 
large number of neuromodulators interfere with the release of GABA and glycine from 
inhibitory dorsal horn neurons via activation of G protein coupled receptors and inhibition of 
Ca2+ channels (Zeilhofer et al., 2012b). An endocannabinoid and CB1 receptor-mediated 
inhibition of glycine and/or GABA release contributes to spinal sensitization evoked by 
extensive nociceptive input to the dorsal horn (Pernia-Andrade et al., 2009). Microglia 
activated in the dorsal horn in response to peripheral nerve damage down-regulates the 
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expression of the potassium and chloride co-exporter KCC2 in superficial dorsal horn 
neurons thereby shifting the reversal potential of GABA and glycine evoked chloride currents 
to more depolarized values. This shift renders glycinergic and GABAergic input less 
inhibitory (Coull et al., 2005; Coull et al., 2003; Keller et al., 2007), or, if the shift is 
sufficiently large, glycinergic and GABAergic input may even become excitatory and trigger 
action potentials in postsynaptic neurons (Coull et al., 2003).  
 
Figure 3. Four signaling pathways leading to spinal disinhibition in pathological pain states.  
(1) Prostaglandin E2 (PGE2) produced in the spinal cord in response to peripheral inflammation in creases 
cAMP production after activation EP2 receptors (EP2). The subsequent activation of protein kinase A (PKA) 
phosphorylates and inhibits GlyR of the superficial dorsal horn. (2) Peripheral nerve damage activates spinal 
microglia which releases brain-derived neurotrophic factor (BDNF). BDNF down-regulates the expression of 
the potassium/chloride exporter KCC2 leading to an increase in intracellular chloride ([Cl-]i). As a consequence 
GABAergic and glycinergic input becomes less inhibitory (or even excitatory). (3) Several neuromodulators 
including endocannabinoids reduce presynaptic GABA and glycine release rendering dorsal horn neurons more 
excitable. (4) Peripheral nerve damage leads to the down-regulation of the GABA synthesizing enzyme GAD65 
and possible to reduced GABA content in inhibitory dorsal horn neurons. 
 
Pharmacological enhancement of GABAergic synaptic transmission in the dorsal horn should 
be able to reverse pathological pain states that result from reduced presynaptic GABA release 
or from reduced responsiveness of postsynaptic GABAARs. Some of the disinhibitory 
processes discussed above do specifically reduce glycinergic inhibition prompting the 
question whether a potentiation of GABAergic responses would be able to restore proper 
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inhibition in these cases. Many inhibitory dorsal horn neurons, co-release GABA and glycine 
from the same terminals and even from the same vesicles (Bohlhalter et al., 1994; Colin et 
al., 1998; Feng et al., 2005; Todd & Sullivan, 1990; Todd et al. 1996). In most dorsal horn 
neurons inhibitory postsynaptic responses are mediated by GABAAR and GlyRs (Baccei & 
Fitzgerald, 2004; Yoshimura & Nishi, 1995) and even in cells, in which no GABAergic 
component is visible under normal conditions, a GABAergic IPSC component can be 
revealed with benzodiazepines and neurosteroids (Keller et al., 2004; Keller et al., 2001). It is 
thus conceivable that pharmacological enhancement of GABAergic neurotransmission would 
also compensate for reduced glycinergic transmission.  
The situation is more complex in those cases where disinhibition results from changes in the 
transmembrane chloride gradient. As long as the activation of GABAAR or GlyRs remains 
below the threshold of action potential activation, potentiation of GABAAR or GlyR may still 
remain inhibitory. However, as soon as the chloride equilibrium potential reaches the action 
potential threshold, potentiation of GABAAR or GlyR would increase the risk of paradoxical 
GABAergic and glycinergic excitation (Prescott et al., 2006). We discuss this issue below in 
the context of preclinical studies on subtype-selective benzodiazepines.  
 
Spinal GABAAR subtypes mediating antihyperalgesia: evidence from genetically 
engineered mice 
Analgesic or antihyperalgesic actions of benzodiazepines occur after local spinal injection 
suggesting that these effects are mediated by GABAARs expressed in the spinal cord. To 
identify the GABAAR subtypes responsible for these antihyperalgesic effects, “knock-in” 
mice were investigated, in which the α1, α2, α3, or α5-GABAAR subunits had been rendered 
diazepam-insensitive through the introduction of a histamine to arginine (H/R) point 
mutation (Knabl et al., 2008; for information on the different point-mutated mouse strains see 
Rudolph & Möhler, 2004). In wild-type mice, intrathecal diazepam strongly reduced 
hyperalgesia in models of inflammatory or neuropathic pain, but had no effects on acute 
nociceptive pain. This “antihyperalgesic” activity was unchanged in mice, which carried the 
H/R point mutation in the α1 subunit, but strongly reduced in mice, which carried the point 
mutation in the α2 subunit. Mice with point-mutated α3 or α5 subunits showed reduced 
antihyperalgesic activity in some but not in all tests. The different subtypes of 
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benzodiazepine-sensitive GABAARs contribute to spinal antihyperalgesia with the rank order 
α2>α3≥α5>>α1. The GABAAR subtype-dependence of spinal antihyperalgesia hence 
matched well with the expression of the different α subunits in the superficial dorsal horn 
(Bohlhalter et al., 1996; Lorenzo et al., 2014; Paul et al., 2012).  
The lack of a contribution from α1-GABAARs, which mediate the sedative effects of 
diazepam (Rudolph et al., 1999), demonstrates that antihyperalgesia by benzodiazepines can 
be studies in the absence of confounding sedation as long as α1-GABAARs are not activated. 
Such experiments were performed in mice carrying H/R point mutations in the α2, α3, or α5 
subunits in addition to α1 (Knabl et al., 2009). These experiments showed that 
antihyperalgesia could also be obtained after systemic diazepam (and in the absence of 
sedation) and that α2 and α3-GABAAR subtypes were the most relevant subtypes also for 
antihyperalgesia following systemic administration.  
So far, GABAAR point-mutated mice have been used to assess the antihyperalgesic properties 
of benzodiazepines in three pain models, i.e. against zymosan A-induced inflammatory 
hyperalgesia, against neuropathic hyperalgesia induced by chronic constriction injury (CCI) 
of the sciatic nerve and in the formalin test. GABAAR subtypes mediating antihyperalgesia 
are thus clearly different from those mediating sedation (Rudolph et al., 1999), amnesia 
(Rudolph et al., 1999), and the rewarding properties of classical benzodiazepines (Tan et al., 
2010). In the case of the α2- and α3-GABAARs, there is a clear overlap with the receptors 
mediating anxiolysis (Löw et al., 2000) and muscle relaxation (Crestani et al., 2001), and in 
case of α5-GABAAR possibly also with those responsible for benzodiazepine-induced 
cognitive impairment (Dawson et al., 2006). For a comparison of the contribution of the 
different GABAAR subtypes to desired hyperalgesia and other effects see figure 4 E. 
The antihyperalgesic efficacy of diazepam after systemic administration prompts two 
questions. How important are spinal versus supraspinal CNS areas for antihyperalgesia by 
systemic benzodiazepines? Do central effects such as a reversal of anxiety-induced 
hyperalgesia (Andre et al., 2005; Vidal & Jacob, 1982) indirectly contribute to the 
antihyperalgesia by systemic benzodiazepines? The latter question appears relevant in 
particular because α2-GABAARs mediate not only antihyperalgesia but also anxiolysis (Löw 
et al., 2000). These questions were addressed with conditional GABAAR deficient mice 
(hoxb8-α2-/- mice), which lack the GABAAR α2 subunit specifically from the spinal cord and 
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dorsal root ganglia (DRGs) (up to about segment C4). In these experiments, a recently 
developed benzodiazepine site agonists (HZ166; Rivas et al., 2009) was employed which 
exerts antihyperalgesic actions similar to systemic diazepam but with reduced sedative and 
muscle relaxant properties (Di Lio et al., 2011). Antihyperalgesia was assessed as the change 
in heat and pin-prick induced withdrawal responses. These withdrawal responses are under 
strong control from descending pain modulating fiber tracts from various CNS areas 
(Carrasquillo & Gereau, 2007; Harris & Westbrook, 1995; Jasmin et al., 2003; Tatsuo et al., 
1999) enabling the analysis of effects of descending (facilitating or inhibitory) pain 
modulation. Mice lacking the GABAAR α2 subunits specifically from the spinal cord showed 
virtually the same reduction in benzodiazepine-induced antihyperalgesia as global α2 (H/R) 
point-mutated mice confirming that the spinal cord was the most relevant site for the 
antihyperalgesic action of benzodiazepines also after systemic administration (Paul et al., 
2014). This finding also largely ruled out secondary effects such as a reversal of anxiety-
induced hyperalgesia. In this context it should also be added that the spinal cords of hoxb8-
α2-/- mice completely lacked α2-GABAARs indicating that the spinal terminals of fibers 
descending from supraspinal CNS areas to the spinal cord do not express α2-GABAARs.  
 
Mechanisms of spinal benzodiazepine-mediated antihyperalgesia 
Immunohistochemistry studies have identified specific spinal distribution patterns of 
GABAAR subunits (Bohlhalter et al., 1996; Paul et al., 2012, figure 4 A - D). These receptors 
are expressed on intrinsic dorsal horn neurons and on the central terminals of primary sensory 
nociceptors. Spinal antihyperalgesia may therefore originate either from classical 
postsynaptic inhibition mediated by GABAARs on intrinsic dorsal horn neurons or from 
GABAARs on nociceptor terminals which mediate presynaptic inhibition through so called 
primary afferent depolarization. Both processes are illustrated in figure 5. The availability of 
a “floxed” α2-GABAAR allele for conditional gene deletion allowed experiments 
distinguishing between these two possibilities.  
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Figure 4. Distribution of α1, α2, α3, and α5-GABAAR subunits in the lumbar spinal cord and 
contribution of the four subtypes of GABAARs to antihyperalgesia.  
(A - D) Immunocytochemical analysis of the expression of GABAAR a subunits in the spinal dorsal horn of 
mice (reproduced from Paul et al., 2012). Scale bar, 100 µm. (E) Contribution of the different GABAAR subtype 
to spinal antihyperalgesia and comparison with other behavioral effects of benzodiazepines (modified from 
Zeilhofer et al., 2009a).  
 
Contribution of presynaptic inhibition and primary afferent depolarization 
To assess the contribution of presynaptic inhibition, the α2-GABAAR subunit was ablated 
specifically from nociceptor terminals using an sns::cre BAC transgenic mouse which 
expresses the cre recombinase under the transcriptional control of the scn10 (Nav1.8) gene 
(Agarwal et al., 2004). In the case of an inflammatory pain model, the degree of 
antihyperalgesia by spinally applied diazepam in the nociceptor-specific α2-GABAAR 
subunit deficient (sns-α2-/-) mice fell between that measured in wild-type mice and global 
α2-GABAAR point-mutated mice. The partial loss of diazepam-induced antihyperalgesia in 
the inflammatory model clearly indicated a contribution of presynaptic inhibition / primary 
afferent depolarization to antihyperalgesia by intrathecal diazepam. This was different in a 
neuropathy model in which all three genotypes responded with virtually identical 
antihyperalgesia (Witschi et al., 2011). Unaltered efficacy in the neuropathy model either 
indicates that antihyperalgesia was entirely due to postsynaptic inhibition of intrinsic dorsal 
horn neurons, or that antihyperalgesia occurred through inhibition of cre-negative (non-
nociceptive) fibers. It has indeed been shown that inflammatory and neuropathic hyperalgesia 
depend on different classes of sensory fibers with Nav1.8 (sns) expressing sensory neurons 
being particularly important for inflammatory pain (Abrahamsen et al., 2008).  
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The results obtained in nociceptor-specific α2-/- mice show that at least part of the 
antihyperalgesia originates from enhanced presynaptic inhibition and primary afferent 
depolarization. The remaining α2-GABAAR-mediated component may result either from 
primary afferent depolarization of non-nociceptive fibers or from postsynaptic inhibition of 
intrinsic dorsal horn neurons. In both cases, the complete loss of α2-GABAAR-mediated 
antihyperalgesia in hoxb8-α2-/- mice unequivocally demonstrates that the major component 
of benzodiazepine-evoked antihyperalgesia is of spinal origin (Paul et al., 2014). This has not 
yet been formally proven for the α3- and α5-GABAAR-mediated components. However, 
both subunits are also enriched in the dorsal horn and their antihyperalgesic actions may thus 
also come from the spinal cord.  
Mechanisms of presynaptic inhibition 
It is well established that the spinal terminals of primary sensory neurons carry functional 
benzodiazepine-sensitive GABAARs. Activation of these presynaptic GABAARs causes 
depolarization of sensory neurons rather than hyperpolarization because primary afferent 
sensory neurons lack an efficient chloride export mechanism (Kanaka et al., 2001; Price et 
al., 2006). As a consequence, the intracellular chloride concentration in these neurons renders 
the chloride equilibrium potential more positive than the resting membrane potential. This 
depolarization is however still inhibitory probably because it leads to a voltage-dependent 
inactivation of Na+ and Ca2+ channels in the axon and the axon terminal, respectively, and 
subsequently reduces transmitter release (Kullmann et al., 2005). This presynaptic inhibition 
can occur through axo-axonic synapses. Their existence is firmly established for non-
nociceptive primary sensory fibers (Aβ and low threshold Aδ fibers; Ribeiro-da-Silva, 1995). 
Axo-axonic contacts have also been found in nociceptor terminals, but less frequently than in 
terminals of non-nociceptive fibers (Alvarez et al., 1993; Ribeiro-Da-Silva et al., 1986; 
Ribeiro-da-Silva et al., 1989). Two recent studies disagree on the presence of gephyrin 
clusters on nociceptor terminals (Lorenzo et al., 2014; Paul et al., 2012). Because gephyrin is 
required for postsynaptic clustering of inhibitory neurotransmitter receptors in central 
neurons, the presence or absence of gephyrin clusters from sensory fiber terminals may be 
taken as an argument in favor or against the presence of axo-axonic synapses between 
GABAergic interneurons and nociceptor terminals. Physiological studies have established 
that primary afferent depolarization and presynaptic inhibition exist also in nociceptors (Lin 
et al., 1999; Lin et al., 2000; Witschi et al., 2011). Nociceptor terminals lacking GABAergic 
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axo-axonic synapses may undergo to presynaptic inhibition through GABAAR via “spill-
over” of GABA from neighboring synapses and so called volume transmission (figure 5; 
Rudomin & Schmidt, 1999, for a more recent review see also Zeilhofer et al., 2012b).  
 
Antihyperalgesic action of benzodiazepines with improved subtype-specificity: 
preclinical studies 
A number of benzodiazepines with reduced activity at α1-GABAARs have been developed in 
the last two decades mainly in the quest for non-sedating anxiolytics (for a comprehensive 
list see (Rudolph & Knoflach, 2011). Because benzodiazepine-mediated anxiolysis and 
antihyperalgesia share a similar dependence on GABAAR subtypes, some of these 
compounds were also tested in pain studies (table 1). Some of these compounds are 
sometimes referred to as “α2/3 selective” (e.g. Hofmann et al., 2012), this is however 
incorrect as all of them are also agonists at α5-GABAARs. This should not be forgotten when 
undesired effects of these compounds are discussed. NS11394, which has very low activity at 
α1-GABAARs (<10% relative to diazepam) and good partial agonistic activity at α2-, α3-, 
and α5-GABAARs (26 – 78%, relative to diazepam) (Mirza et al., 2008), exhibited 
antinociceptive activity at non-sedating doses in several rodent pain models (Hofmann et al., 
2012; Munro et al., 2008). The analgesic effect in the formalin test was blocked by the 
benzodiazepine site antagonist flumazenil (Munro et al., 2008) confirming that it occurred 
through GABAARs. L-838,417, which completely lacks intrinsic activity at α1-GABAARs 
and possesses partial agonistic activity at α2-, α3-, and α5-GABAARs (15 – 32%, relative to 
diazepam; McKernan et al., 2000), was tested in several rodent pain models where it was not 
sedative but active against inflammatory and neuropathic hyperalgesia (Knabl et al., 2008; 
Nickolls et al., 2011) and formalin-induced nociception (Hofmann et al., 2012). 
In addition, L-838,417 was active against hyperalgesia evoked by skin incision, a model of 
postoperative hyperalgesia (Reichl et al., 2012) and against capsaicin-induced central pain 
sensitization (Hansen et al., 2012). Other benzodiazepines with low sedative propensities 
include HZ166 (Rivas et al., 2009) and TPA023 (Atack et al., 2006). HZ166, which has high 
intrinsic activity, was antihyperalgesic in inflammatory and neuropathic mouse models (Di 
Lio et al., 2011), while TPA023, which is a low intrinsic activity partial agonist, showed 
comparatively weak anti-allodynic or antihyperalgesic effects (Munro et al, 2011; Nickolls et 
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al., 2011). Other compounds, which have higher intrinsic activities at α1-GABAARs than at 
α2-, α3-, and α5-GABAARs, did not exhibit antihyperalgesic activity at non-sedative doses. 
These results are fully consistent with the results obtained from H/R point-mutated mice. 
 
 
Figure 5. Mechanisms of the GABAergic control of spinal pain transmission.  
(A) Anatomical arrangement of pre- and postsynaptic inhibition. (B) Activation of GABAARs on nociceptor 
terminals causes chloride efflux and primary afferent depolarization (left panel). This primary afferent 
depolarization causes a presynaptic inhibition of synaptic glutamate release from nociceptor terminals (middle 
panel). Activation of GABAARs on second order neurons (intrinsic) dorsal horn neurons activates chloride 
influx and causes classical postsynaptic inhibition through hyperpolarization and dendritic shunting (right 
panel).  
 
Novel benzodiazepines for treatment of chronic pain would not only have to have good 
analgesic or antihyperalgesic efficacy and low or at least weak sedative properties, but would 
also have to avoid other typical side effects of benzodiazepines such as addiction and 
tolerance development (i.e. a loss of activity during prolonged treatment).  
Addiction 
Reinforcing (or addictive) properties were absent or reduced in the case of partial agonists 
which lack efficacy at α1-GABAARs, including L-838,417 (Rowlett et al., 2005) and 
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TPA023 (Abe et al., 2009). Other partial agonists with higher efficacy at α1-GABAARs such 
as TPA123 caused a withdrawal syndrome following upon cessation of self-administration, 
suggesting that the lack of agonistic activity at α1-GABAARs was the relevant parameter 
rather than a general reduction in agonistic activity (Ator et al., 2010). These results are 
consistent with studies in α1-GABAAR point-mutated mice, in which no reinforcement was 
seen with the full agonist midazolam (Tan et al., 2010).  
Tolerance development against antihyperalgesia 
Analgesia by opioids shows a high liability to tolerance development and the same applies to 
many of the actions of classical benzodiazepines including antihyperalgesia in rats (Witschi 
& Zeilhofer, unpublished) and mice (Ralvenius et al., 2013). Whether tolerance against 
antihyperalgesia occurs also with more selective or non-sedative benzodiazepines has been 
studied for three compounds. L-838,417 was devoid of tolerance developments against 
antihyperalgesic / analgesic actions during chronic nine day treatment, while an equally 
effective dose of morphine completely lost its antihyperalgesic activity during the same time 
period (Knabl et al., 2008). Tolerance development was also not observed against 
antihyperalgesia by HZ166 (Di Lio et al., 2011), whereas NS11394 lost at least part of its 
analgesic activity against formalin-induced pain during chronic eight-day treatment 
(Hofmann et al., 2012). It is at present unknown whether reduced tolerance liability of non-
sedative or more selective benzodiazepines is due to their reduced intrinsic activity (partial 
agonism), to improved subtype-selectivity, or to pharmacokinetic differences. Mice carrying 
different combinations of point-mutated GABAAR α subunits should offer a tool to address 
these possibilities. 
 
Clinical studies on antihyperalgesia by benzodiazepines 
The preclinical studies discussed above performed in mice resistant to the sedative effects of 
benzodiazepines demonstrate that classical benzodiazepines do in principle exert profound 
antihyperalgesic actions but only at doses, which normally induce strong sedation. Less 
sedating benzodiazepines exhibited antihyperalgesic efficacy at non-sedating doses also in 
wild-type mice.  
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In human patients, classical non-selective benzodiazepines do not exert relevant analgesic (or 
antihyperalgesic) actions at clinically used doses. The few publications that found positive 
evidence for efficacy in pain patients were pilot studies or open trials (e.g. Fishbain et al., 
2000; Harkins et al., 1991), which provide only limited evidence. Possible explanations for 
this lack of analgesic or antihyperalgesic efficacy in humans include (1) species differences 
(rodents versus humans), (2) biological differences between preclinical models of pain and 
pain in human patients, and (3) dose limiting sedation after systemic administration of 
classical benzodiazepines. The authors of this review favor the latter possibility for several 
reasons.  
A recent study investigated possible analgesic or antihyperalgesic effects of two classical 
benzodiazepines (clobazam and clonazepam) in a battery of pain tests in human volunteers 
(Vuilleumier et al., 2013). This study found of a (small) antihyperalgesic effect in several 
parameters including in the size of the hyperalgesic area induced by intracutaneous capsaicin 
injection and in several muscle pain-related read-outs. Non-selective full agonists such as 
diazepam, clonazepam, midazolam typically induce strong sedation or sleep already at 
receptor occupancies between 15 and 30% (Fujita et al., 1999; Malizia et al., 1995; Pauli et 
al., 1991; Shinotoh et al., 1989). Compounds with a better α2/α1-selectivity ratio should 
permit higher levels of receptor occupancy and hence higher α2-GABAAR activation before 
reaching dose-limiting sedation. 
The data available from the few benzodiazepines with improved selectivity profile that went 
into clinical trials provide some insight as to what degree of selectivity would be needed to 
avoid sedation in humans. One such study investigated MK-0343 (also known as MRK-409), 
which has very weak agonistic activity at α1-GABAARs (18% relative to the full agonist 
chlordiazepoxide; Atack et al., 2011). This compound was sedative in humans although 
previous preclinical tests in rodents had not shown any evidence for sedative properties 
(Atack et al., 2011; de Haas et al., 2008). A related compound (TPA023B) fully devoid of 
agonistic activity at α1-GABAARs did not produce sedation in man (Atack et al., 2011). 
These results suggest that the human brain is more susceptible to sedative actions of 
benzodiazepines than that of mice and rats (or, alternatively one might argue that our tests to 
assess sedation on rodents are less sensitive than those in man). In both cases the available 
data indicate that sedation in humans can be avoided with compounds fully devoid of 
intrinsic activity at α1-GABAARs. Concert Pharmaceuticals is currently performing a phase 1 
INTRODUCTION 
- 48 - 
clinical trial on a deuterated version of L-838,417 (now called CTP-354), which has more 
favorable pharmacokinetics in humans than L-838,417 (http://www.concertpharma.com/ 
CTP354Phase1Initiation.htm). It would be very informative to see whether CTP-354 or 
TPA023B, which has an intrinsic activity at α2-GABAARs even higher than that of L-
838,417 and no agonistic activity at α1-GABAARs, possess antihyperalgesic or analgesic 
activity in human volunteers or pain patients. 
 
Open questions 
Which GABAAR subtypes should be targeted for optimal analgesia with minimal side-
effects? 
Work in the GABAAR H/R point-mutated mice suggests that α2-, α3-, and α5-GABAARs 
contribute to spinal benzodiazepine antihyperalgesia. It is however not clear whether only 
one subtype (i.e. α2-GABAARs) should be targeted for optimal antihyperalgsia or whether 
simultaneous activity at more than one subunit would be advantageous. In the absence of 
fully selective subtype-specific drugs, investigations on mice carrying more than one point 
mutated GABAAR subtype should be informative. When taking undesired effects into 
consideration, one would probably try to avoid positive allosteric modulation of α5-
GABAARs as this modulation might confer cognitive impairment. Another reason to avoid 
activity at α5-GABAARs comes from a recent report suggesting that inverse agonistic 
activity at α5-GABAARs could be analgesic (Munro et al., 2011). So far, one would not 
expect undesired effects from activity at α3-GABAARs, however it is at present unknown if 
development of tolerance against the α2-mediated antihyperalgesic activity can be avoided 
by sparing activity at other GABAAR subtypes. This is again a question, which is potentially 
accessible to studies examining mutant mice carrying combinations of H/R point-mutated 
GABAAR subunits.  
The genetic approaches described in this review are very well suited for experiments 
addressing the function of precisely defined GABAAR subtypes. It is however not clear 
whether structural differences in the benzodiazepine binding site of different GABAAR 
subtypes are large enough to permit development of subtype-selective benzodiazepines for 
each subtype or subtype combination. In particular differences between α2 and α3 subunits 
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might be too small to permit subtype specificity. Searching for modulatory sites at GABAARs 
different from the classical benzodiazepine binding site might offer an alternative very 
intriguing, yet so far largely unexplored, opportunity. 
 
Mixed GABAARs with more than one type of α  subunit 
One potential limitation of the H/R point mutation approach is the behavior of GABAARs 
with more than one type of α subunit. More than 25% of α1 containing GABAARs contain a 
second α subunit different from α1 (mainly α2 or α3), and the majority of α2 and α3 
GABAARs are mixed receptors (Benke et al., 2004). Because only one of the two α subunits 
can interact with the γ subunit to form the high affinity benzodiazepine binding site, the 
responses of these mixed receptors to fully subtype selective compounds will be determined 
by the type of α subunit which associates with the γ subunit (Minier & Sigel, 2004). This 
association may occur randomly but biochemical data suggest a certain rank order of the α 
subunits for interaction with the γ2 subunit (Balic et al., 2009). Moreover, biochemical 
experiments suggest that the H/R point mutation in the α subunit not only abolishes 
modulation by diazepam but also impairs the interaction with the γ subunit. This may 
eventually lead to false negative results in experiments with H/R point-mutated mice and may 
contribute to some of the discrepancies between predictions made from the H/R point-
mutated mice and results obtained with subtype-selective agents (Sigel & Steinmann, 2012; 
Skolnick, 2012). If differences in the prevalence of the different types of mixed GABAARs 
exist between mice and humans, these differences may also explain some of the discrepant 
results obtained in rodent models and in clinical studies. Experiments comparing the 
phenotypes of single point-mutated mice and of triple point-mutated mice in which only a 
single subtype remains benzodiazepine-sensitive may provide additional insights also here.  
Conclusions 
There is compelling evidence from preclinical studies in rodents to support that non-sedative 
benzodiazepines with improved subtype specificity exert antihyperalgesic effects. Available 
clinical data are consistent with this view. Current knowledge suggests that robust 
antihyperalgesic activity with low sedative properties requires a high intrinsic activity at α2-
GABAARs (or possibly also at α3-/α5-GABAARs) and very low or little activity at α1-
INTRODUCTION 
- 50 - 
GABAARs. The optimal profile of such a drug in terms of GABAAR subtype specificity is 
however still not known. On-going preclinical studies and clinical trials will hopefully soon 
provide additional insights.  
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2 AIMS 
As described above, a dysfunction of the inhibitory system on a spinal level can lead to 
hyperalgesia and allodynia, which are hallmarks of chronic pain states. Potentiating the spinal 
GABAergic inhibition through intrathecal benzodiazepine injection has been shown to 
compensate for this disinhibition (Knabl et al., 2008). Studies in mice carrying point 
mutations in single GABAA receptors have provided first insights into the contribution of the 
different GABAA receptor subtypes. However, they did not provide a comprehensive analysis 
of desired and undesired effects expected from subtype-selective GABAergic drugs.  
2.1 The first project of the present thesis was designed to address the following specific 
questions: 
(1) what is the distribution of GABAA receptor subtypes (not subunits) in the spinal cord? 
(2) which GABAA receptor subtype should be targeted to achieve maximal antihyperalgesia 
with minimal side-effects? 
(3) why do classical benzodiazepines lack clinically relevant analgesic efficacy? 
2.2 The second project of this thesis was designed to help translating the results of 
rodent studies on antihyperalgesic properties of GABAA receptor subtypes to clinical 
application. 
None of the currently available subtype-selective GABAA receptor modulators developed by 
pharmaceutical industry in recent years is currently available for proof-of-concept studies in 
man. I therefore evaluated alternative approaches. N-desmethyl clobazam (NDMC) is a 
naturally occurring metabolite of the clinically used benzodiazepine clobazam (CBZ). 
Previous studies have suggested that NDMC might exhibit an improved α2/α1 GABAA 
receptor activity ratio.  
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The second part of my thesis was therefore designed to address the following specific aims: 
(1) how does the in vitro pharmacological profile of NDMC compare to those of the parent 
compound CBZ and the prototypical benzodiazepine diazepam? 
(2) what are the dose-dependencies of NDMC-evoked antihyperalgesia and sedation in 
comparison to CBZ? 
(3) do side-effects different from sedation occur with NDMC at antihyperalgesic doses? 
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Abstract 
Agonists at the benzodiazepine-binding site of GABAA receptors (BDZs) enhance synaptic 
inhibition through four subtypes (α1, α2, α3, α5) of GABAA receptors (GABAARs). When 
applied to the spinal cord, they alleviate pathological pain, but insufficient efficacy after 
systemic administration and undesired effects preclude their use in routine pain therapy. 
Previous work suggested that subtype-selective drugs might allow separating desired 
antihyperalgesia from unwanted effects, but the lack of selective agents has hitherto 
prevented systematic analyses. Using four lines of triple GABAAR point-mutated mice, 
which expressed only one benzodiazepine-sensitive GABAAR subtype at a time, we found 
that strong antihyperalgesia and reduced side-effects (i.e. no sedation, motor impairment, and 
tolerance development) are best achieved when only α2GABAARs are targeted. Additional 
pharmacokinetic/pharmacodynamic analyses in these mice explain why clinically relevant 
antihyperalgesia cannot be achieved with non-selective BDZs. These findings should strongly 
foster the development of innovative subtype-selective BDZs for novel indications including 
chronic pain. 
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Introduction 
Chronic pain is a severe medical condition affecting hundreds of millions of patients world-
wide. It is widely accepted that diminished inhibition in pain processing circuits of the spinal 
dorsal horn is a major contributor to different chronic pain forms (Zeilhofer et al., 2012; De 
Koninck, 2007; Kuner, 2010; Sandkühler, 2009). We have previously demonstrated that local 
spinal application of BDZ site ligands that positively modulate GABAAR function alleviates 
neuropathic and inflammatory pain in rodents (Knabl et al., 2008). Translation of these 
results to routine systemic pain treatment however requires a separation of desired 
antihyperalgesia from unwanted side-effects. This separation appears potentially feasible 
based on the existence of different GABAAR subtypes.  
Most GABAARs in the brain and spinal cord are heteropentameric ion channels composed of 
two α, two β and one γ2 subunit (Sigel et al., 2006). The high affinity binding site for BDZs 
is formed by an interface between one α subunit and the γ2 subunit. High affinity binding of 
BDZs at this site requires presence of a histidine residue at a conserved site in the N-terminal 
domain of the α subunit. This conserved histidine is present in α1, α2, α3, or α5 subunits, 
but not in α4 and α6 subunits (Wieland et al., 1992). Mutation of the histidine residue into an 
arginine dramatically reduces the affinity of GABAARs to BDZs without changing their 
responses to GABA (Benson et al., 1998). The generation of histidine to arginine (H → R) 
point-mutated mice for each of the four BDZ-sensitive GABAAR subunits has allowed 
attributing the different in vivo effects of BDZs to defined GABAAR subtypes (Möhler et al., 
2005). Most importantly, it was shown that the sedative effects of BDZs were strongly 
reduced in mice carrying the H → R point mutation in their α1 subunits (McKernan et al., 
2000; Rudolph et al., 1999), while point mutating the α2 subunits led to a loss in the 
anxiolytic effects of BDZs (Löw et al., 2000). Using this approach, we could demonstrate 
that mice whose α2GABAARs had been rendered BDZ-insensitive show drastically reduced 
antihyperalgesic responses to spinal diazepam (DZP) (Knabl et al., 2008). A general 
consensus on the question, which GABAAR subtype should best be targeted to achieve 
maximal antihyperalgesic responses and to best avoid undesired effects has not been reached. 
A similarly open question is why classical BDZs are largely devoid of analgesic actions in 
patients.  
Highly selective tool compounds that would allow addressing these questions 
pharmacologically are still lacking (Rudolph & Knoflach, 2011). For this reason, we have 
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generated triple GABAAR point-mutated mice, in which only a single GABAAR subtype 
remains BDZ-sensitive. We designate these mice hereafter as HRRR, short for 
α1H;α2R;α3R;α5R (i.e. a mouse in which only α1GABAARs are left BDZ-sensitive) and, 
accordingly, as RHRR, RRHR, RRRH for mouse lines, in which either only α2, α3, or α5 
subunits remain BDZ-sensitive. In these mice, the action of the classical normally non-
selective BDZ agonist DZP should mimic the action of fully subtype-selective compounds. 
Such a genetic approach also avoids possible confounding factors of subtype-selective 
compounds such as pharmacokinetic differences and unknown specificity profiles of drug 
metabolites. With the use of triple GABAAR point-mutated mice, we were not only able to 
perform a systematic analysis on the GABAAR subtypes best targeted for optimal 
antihyperalgesia and least-pronounced side-effects but we also provide an explanation why 
classical (non-selective) BDZs are largely devoid of clinically relevant analgesic properties.  
 
Results  
Spinal distribution of subtype-specific BDZ binding sites  
In the first series of experiments, we characterized the distribution pattern of the four 
subtypes of BDZ-sensitive GABAARs (“BDZ receptors”) in the spinal dorsal horn of triple 
point-mutated mice. Using immunocytochemistry, we verified that neither the regional 
distribution nor the expression levels of α1, α2, α3, and α5 subunits and of the γ2 subunit 
differed between wild-type (wt) mice and the four strains of triple point-mutated mice (Fig. 1 
A,B). Similarly, the total number of BDZ binding sites (wt receptors plus H → R point-
mutated receptors) quantified through [3H]Ro15-4513 autoradiography was unchanged (Fig. 
1 C). Spinal autoradiography with [3H]flumazenil which binds with high affinity only to non-
point-mutated GABAARs allowed a quantitative analysis of each of the four subtypes of BDZ 
binding sites in isolation. In wt mice, [3H]flumazenil exhibited specific binding throughout 
the spinal grey matter with enrichment in the dorsal horn and around the central canal. The 
density of binding sites in the dorsal horn was highest for the α3GABAAR subtype, followed 
by α2 and α1, and lowest for the α5 subtype (Fig. 1 D). The α1 subtype was concentrated 
around the central canal, α2 was most abundant in the superficial dorsal horn, where 
nociceptive fibers terminate, α3 was found throughout the dorsal horn and around the central 
canal, while α5 was generally weak. The distribution of subtype-specific [3H]flumazenil 
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binding in the four strains of GABAAR triple point-mutated mice matched the distribution of 
the subunits determined with immunocytochemistry on a gross scale.  
 
 
Figure 1. Distribution of the four subtypes of BDZ-sensitive GABAARs in the spinal cord.  
(A,B) Immunohistochemistry. (A) Localization of GABAAR α subunits in spinal cords of wt mice and of the 
four types of GABAAR triple point-mutated mice. Pseudocolor images display receptor density (lowest to 
highest density, blue to yellow). Right: quantitative comparison of expression levels in wt and triple point-
mutated mice. Two-way ANOVA for interaction (α subunit x genotype): F(7,42)=0.53, P=0.68. n=6 mice (3 
sections each) for all groups, except RRHR, where n=7 mice. (B) Same as (A) but for γ2 subunits. ANOVA 
followed by Dunnett’s post hoc test. F(4,15)=0.32; P≥0.94. n=4 mice (3 sections each) for all genotypes. (C,D) 
Autoradiography. (C) [3H]Ro15-4513 binding sites indicate the distribution of all α/γ GABAARs independent of 
their BDZ-sensitivity in wt mice and the four types of GABAAR triple point-mutated mice. H and R indicate 
homozygous wt and point-mutated alleles (for α1/α2/α3/α5 subunits), respectively. Right: quantification of 
[3H]Ro15-4513 binding sites in the dorsal horn. ANOVA followed by Dunnett’s post hoc test with wt as 
control. F(4,10)=2.89, P≥0.18. n=3, for all genotypes (> 30 sections each). (D) Same as (C) but distribution of 
BDZ-sensitive GABAARs labeled with [3H]flumazenil. ANOVA followed by Dunnett’s post hoc test with wt as 
control. F(4,55)=40.1, ***; P<0.001. n=11, 12, 12, 12, and 14 mice (> 10 sections each), for wt(HHHH), 
HRRR, RHRR, RRHR, and RRRH mice, respectively. (E) Same as (D) but wt and GABAAR single point-
mutated mice. F(4,42)=0.441; P>0.66. n=11, 9, 9, 9, and 9 mice, for wt(HHHH), RHHH, HRHH, HHRH, and 
HHHR mice, respectively. All scale bars, 200 µm. All quantitative data mean ± SEM. 
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However, the sum of the binding sites in the four strains of triple point-mutated mice was 
about twice as high as the total number of binding sites in wt mice. The results from the 
immunocytochemistry and [3H]Ro15-4513 autoradiography largely rule out changes in 
protein expression as the underlying cause. Instead, the [3H]flumazenil data are consistent 
with a high prevalence of GABAARs containing two different α subunits (Araujo et al., 1996; 
Benke et al., 2004) and with a model of the GABAAR assembly in which non-point-mutated 
α subunits have a higher probability for interaction with the γ2 subunit than H → R point-
mutated subunits (Balic et al., 2009). This conclusion is further supported by the only 
marginal reduction of BDZ binding observed in spinal cords of the four single point-mutated 
mouse lines (Fig. 1 E).  
Antihyperalgesia by single BDZ-sensitive GABAARs subtypes 
We next used the triple point-mutated mice to predict pharmacological actions of subtype-
selective BDZ site agonists and treated them with DZP, a classical non-selective BDZ, whose 
agonistic activity was restricted to a single GABAAR subtype in triple point-mutated mice. 
We first focused on the antihyperalgesic potential of such an approach (i.e. the potential to 
reduce neuropathy-induced hyperalgesia) and tested DZP in mice subjected to the chronic 
constriction injury (CCI; Bennet & Xie, 1988) model. Baseline mechanical and heat 
sensitivity were statistically indistinguishable in all strains of mice analyzed and all strains of 
mice developed similar hyperalgesia after CCI (Tab. 1). All subsequent experiments with 
DZP were done on an α1R point-mutated background to avoid DZP-induced sedation, which 
is a potential confounding factor in behavioral pain tests. We first tested different doses of 
systemic (per os, p.o.) DZP in α1 point-mutated RHHH mice (Fig. 2 A,B). Based on these 
results, we chose a dose of 10 mg/kg body weight, which is close to the ED70 for subsequent 
experiments. We then asked which GABAAR subtype exerts the strongest antihyperalgesic 
action and tested the effects of DZP on mechanical (von Frey filament test) and heat 
(Hargreaves test) hyperalgesia in the four strains of triple GABAAR point-mutated mice (Fig. 
2 C-E). For both stimuli, the strongest effect was achieved in RHRR mice in which only 
α2GABAARs were BDZ-sensitive. Exclusive targeting of α3 and α5GABAARs (in RRHR 
and RRRH mice) also elicited antihyperalgesia but to a smaller extent.  
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Figure 2. Antihyperalgesia by per oral DZP in GABAAR point-mutated mice.  
(A) Reversal of mechanical hyperalgesia by DZP in α1 point-mutated (RHHH) mice assessed with von Frey 
filaments 7 days after CCI surgery. (B) Dose-response relationship. Data were fitted to Hill’s equation. ***, 
P<0.001; **, P<0.01 versus vehicle (ANOVA F(4,28)=29.0 followed by Dunnett’s post hoc test. n=7, 7, 6, 7, 
and 6 mice, for vehicle and 1, 10, and 30 mg/kg DZP, respectively). (C,D) Reversal of mechanical (C) and heat 
hyperalgesia (D) by DZP (10 mg/kg) one week after CCI surgery. All mice except wt carried the H→R point-
mutation in α1GABAARs to avoid sedation. (E) Comparison of antihyperalgesia (determined from 70 to 130 
min after DZP administration) in GABAAR triple point-mutated mice. ***, P<0.001; **, P<0.01; versus 
vehicle-treated wt mice (ANOVA followed by Dunnett’s post hoc test, F(4,54)=36.2 and F(4,53)=15.1 for von 
Frey and Hargreaves tests, respectively). No antihyperalgesia by DZP occurred in quadruple GABAAR point-
mutated mice (P=0.85 and 0.94). (F) Comparison of antihyperalgesia by DZP in RHRR mice with that of mice 
carrying in addition BDZ-sensitive α3 and/or α5GABAARs. No significant differences were observed (ANOVA 
followed by Dunnett’s post hoc test, von Frey: F(3,57)=2.96; P≥0.12. Hargreaves: F(3,44)=0.98; P≥0.37). (G) 
Antihyperalgesia in triple GABAAR point-mutated mice with only one DZP-sensitive GABAAR subtype (grey 
columns) compared to antihyperalgesia lost through H→R point mutation of the same subunit (light red 
columns). Antihyperalgesia in triple point-mutated mice is expressed as percentage of antihyperalgesia in 
RHHH mice. Loss of antihyperalgesia was calculated as the reduction in antihyperalgesia relative to RHHH 
mice. ***, P<0.001; **, P<0.01; *, P<0.05 (unpaired t-tests). Number of mice in (C-G): vehicle-treated wt (von 
Frey/Hargreaves test) n=7/11, RHHH n=15/12, RHRR n=18/19, RRHR n=13/9, RRRH n=11/12, RHHR 
n=19/10, RHRH n=9/7, RRRR n=9/6, RRHH n=8/19. (H) Formalin test. Reduction by DZP (10 mg/kg) in the 
number of flinches and licking bouts compared to vehicle-treated mice. ***, P<0.001; **, P<0.01; *, P<0.05 
(ANOVA followed by Dunnett’s post hoc test. Flinches, F(3,24)=6.71; licking bouts, F(4,25)=10.7. n=9, 6, 7, 
and 6 mice, for vehicle-treated wt, and DZP-treated RHRR, RRHR, and RRRH mice, respectively. All data 
points are mean±SEM. 
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Table 1: Baseline nociceptive sensitivities of all GABAAR genotypes under study 
  pre-CCI post-CCI 
genotype BDZ-sensitive 
α subunit(-s) 
von Frey (g) 
(number of 
mice) 
Hargreaves (s) 
(number of 
mice) 
von Frey (g) 
(number of 
mice) 
Hargreaves (s) 
(number of 
mice) 
HHHH  
(wt) 
α1,α2,α3,α5 4.04 ± 0.07 
(20) 
22.9 ± 0.72 
(17) 
1.48 ± 0.23 
(8) 
11.7 ± 1.03 
(16) 
RHHH α2,α3,α5 4.41 ± 0.11 
(23) 
22.6 ± 0.63 
(15) 
1.52 ± 0.11 
(15) 
9.68 ± 0.81 
(12) 
RHHR α2,α3 4.21 ± 0.12 
(26) 
23.4 ± 0.57 
(15) 
1.46 ± 0.09 
(20) 
10.4 ± 1.15 
(10) 
RHRH α2,α5 4.05 ± 0.09 
(23) 
22.9 ± 0.60 
(20) 
1.26 ± 0.10 
(9) 
12.8 ± 1.70 
(7) 
RRHH α3,α5 4.23 ± 0.04 
(29) 
21.0 ± 0.43 
(29) 
1.52 ± 0.06 
(8) 
8.54 ± 0.62 
(19) 
RHRR α2 4.12 ± 0.06 
(32) 
22.2 ± 0.53 
(32) 
1.42 ± 0.11 
(18) 
10.7 ± 0.72 
(19) 
RRHR α3 4.12 ± 0.12 
(29) 
22.2 ± 0.50 
(29) 
1.27 ± 0.08 
(13) 
10.3 ± 1.00 
(9) 
RRRH α5 4.32 ± 0.07 
(23) 
21.5 ± 0.42 
(23) 
1.67 ± 0.08 
(11) 
10.2 ± 0.89 
(12) 
RRRR none 3.99 ± 0.10 
(9) 
20.8 ± 1.48 
(6) 
1.18 ± 0.16 
(9) 
10.3 ± 1.51 
(6) 
statistics  F(8,205) =  
1.57;  
P ≥ 0.06 
F(8,177) = 
1.93; 
P ≥ 0.06 
F(8,102) = 
1.78; 
P ≥ 0.16 
F(8,101) = 
1.80; 
P ≥ 0.09 
values are given as mean±SEM 
ANOVA followed by Dunnett’s post hoc test with wt (HHHH) as control.  
 
Importantly, mice in which all four BDZ receptors had been point-mutated (RRRR mice) did 
not show any antihyperalgesic response. We next asked whether targeting of a second or third 
GABAAR subtype in addition to α2 would increase antihyperalgesic efficacy and compared 
antihyperalgesic responses in triple point-mutated mice with those in mice carrying only one 
or two point-mutated receptors. We found only small and statistically insignificant 
differences indicating that adding activity at a subtype different from α2 did not significantly 
increase antihyperalgesia (Fig. 2 F).  
The autoradiography data shown in Fig. 1 D suggest a high prevalence of GABAARs with 
two different α subunits (“mixed GABAARs”) in the spinal cord. Because the sum of the four 
receptor subtypes detected in the triple point-mutated mice greatly exceeded the total number 
of [3H]flumazenil binding sites in the wt mice, the pharmacological effect of a given 
GABAAR subtype may be overestimated when tested in triple point-mutated mice. To 
address this issue, we compared the level of antihyperalgesia achieved in the triple point-
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mutated mice with the loss in antihyperalgesia that occurs after mutation of the same subunit 
(Fig. 2 G). For both types of sensory tests (Hargreaves and von Frey filament) and for all 
three α subunits under study, we found that the level of antihyperalgesia achieved in the 
triple point-mutated mice always exceeded the loss in antihyperalgesia by mutation of the 
same subunit consistent with the high prevalence of mixed GABAARs in the spinal cord. It is 
important to note that the rank order of antihyperalgesic efficacies was the same in 
experiments with triple point-mutated mice and in loss-of-function experiments in single and 
double point-mutated mice, and also identical to those found in a pain model employing 
chemical nociceptor activation instead of neuropathy (Fig. 2 H).  
 
 
 
 
Figure 3. Antihyperalgesia by the non-sedative 
BDZ HZ-166 occurs through α2GABAARs.  
HZ-166 (16 mg/kg, i.p,) almost completely 
reversed CCI-induced mechanical sensitization in 
wt mice (HHHH, black), but not in α2(H101R) 
mice (HRHH mice, red). (B) Statistical analysis. 
**, P<0.01 (unpaired t-test), n=7 and 8 mice, for wt 
and α2(H101R) mice. All data points are 
mean±SEM. 
 
Taken together, these results support a major contribution of α2GABAARs to 
antihyperalgesia in different pain models. However, because all experiments had to be done 
on an α1 point mutated background to avoid confounding sedation, the relevance of 
α2GABAARs might be overestimated if “pain-relevant” α2GABAARs contained also α1 
subunits. To address this potential caveat we used HZ-166 (Rivas et al., 2009), a novel 
benzodiazepine site ligand with an improved α2/α1 selectivity ratio (Fischer et al., 2010) and 
significant analgesic activity already at non-sedative doses (Di Lio et al., 2011) (Fig. 3). 
Antihyperalgesia by HZ-166 was almost completely blocked in single α2(H101R) point 
mutated (HRHH) mice further confirming that the “pain-relevant” GABAARs exhibit an α2 
pharmacology.  
Potential undesired BDZ effects in triple point-mutated mice 
We next used the same triple point-mutated mouse approach to investigate non-pain-related 
effects. In these experiments, we focused on diminished locomotor activity (as a surrogate 
parameter of sedation), muscle strength, and motor coordination. No significant differences 
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were observed in the behavior of drug naïve wt and point-mutated mice (Tab. 2). DZP 
treatment strongly reduced locomotor activity in wt mice and in mice with BDZ-sensitive 
GABAARs of only the α1 subtype (HRRR mice) (Fig. 4 A). No sedative effects were 
observed in any of the other triple point-mutated mice. Mice with only α2 BDZ-sensitive 
GABAARs (RHRR mice) even showed a strong increase in locomotor activity, which may 
originate from the anxiolytic effect of DZP occurring through α2GABAARs (Löw et al., 
2000). 
 
Table 2: Baseline locomotor activity, and performance in the horizontal wire and rotarod tests  
genotype BDZ-sensitive 
α subunit(-s) 
activity counts 
(number of mice) 
horizontal wire 
performance1 
(number of mice) 
rotarod 
performance2 
(number of mice) 
HHHH (wt) α1,α2,α3,α5 962 ± 114 
(14) 
92 ± 2.5 
(17) 
92 ± 5.6 
(5) 
HRRR α1 1102 ± 104 
(9) 
98 ± 1.2 
(9) 
98 ± 8.2 
(6) 
RHRR α2 1132 ± 106 
(8) 
96 ± 1.2 
(8) 
81 ± 5.3 
(5) 
RRHR α3 1279 ± 114 
(10) 
99 ± 1.1 
(10) 
85 ± 7.7 
(5) 
RRRH α5 987 ± 90.4 
(8) 
100 ± 0.0 
(8) 
84 ± 11 
(5) 
RRRR none 1037 ± 115 
(9) 
99 ± 1.2 
(9) 
110 ± 13 
(5) 
statistics3  F(5,52) = 1.16;  
P ≥ 0.13 
F(5,55) = 2.10; 
P ≥ 0.70 
F(5,25) = 1.53; 
P ≥ 0.47 
values are given as mean±SEM 
1horizontal wire performance, expressed as success rate (%) 
2rotarod performance, expressed as time before fall-off (s) 
3ANOVA followed by Dunnett’s post hoc test with wt (HHHH) as control.  
 
Impairment of muscle strength was assessed in the horizontal wire test. Significant muscle 
relaxation was detected in wt mice and in mice with BDZ-sensitive GABAARs of either only 
the α2 (RHRR mice) or α3 subtype (RRHR mice) (Fig. 4 B). Motor coordination, tested in 
the rotarod test, was significantly impaired by DZP in mice with only α1 (HRRR mice) and 
with only α3 BDZ-sensitive GABAARs (RRHR mice) (Fig. 4 C). Quadruple point-mutated 
(RRRR) mice were completely protected from DZP-induced muscle relaxation and motor 
impairment. They did however show a trend towards reduced locomotor activity (compare 
Fig. 4 A). We therefore assessed changes in locomotion also after higher DZP doses in the 
quadruple point-mutated mice and found significant and dose-dependent impairment starting 
at 30 mg/kg (Fig. 4 D). Unlike α1GABAAR-mediated sedation, impairment of muscle 
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strength was absent in the quadruple point-mutated mice even at doses ≥ 30 mg/kg. The 
sedative action of DZP remaining in the quadruple point-mutated mice may be attributed to a 
low affinity BDZ binding site at α1GABAARs described earlier (Drexler et al., 2010, Walters 
et al., 2000).  
 
Figure 4. Sedation, muscle relaxation and motor coordination in GABAAR mutated mice.  
Effects of DZP (10 mg/kg, p.o.) on locomotor activity in the open field test (A), on muscle relaxation in the 
horizontal wire test (B), and on motor coordination in the rotarod test (C). ***, P<0.001; *, P<0.05 significant 
versus vehicle-treated wt (HHHH) mice (ANOVA followed by Dunnett’s post hoc test). Statistics: locomotor 
activity F(6,177)=79.5 (n=106, 26, 8, 8, 9, 13, and 13 mice, for vehicle and DZP-treated wt mice, and DZP-
treated HRRR, RHRR, RRHR, RRRH, and RRRR mice, respectively). Horizontal wire F(6,165)=44.0 (n=109, 
14, 8, 8, 9, 13, and 10 mice). Rotarod F(6,41)=11.5 (n=8, 5, 6, 7, 6, 8, and 8 mice). (D) Effects of DZP on 
locomotor activity and horizontal wire performance in quadruple GABAAR point-mutated (RRRR) mice. ***, 
P<0.001; **, P<0.05 significant versus vehicle (ANOVA followed by Dunnett’s post hoc test) F(3,33)=13.4 
(locomotor activity), n=9, 13, 8, and 7 mice, for vehicle, and 10, 30, and 100 mg/kg DZP; F(3,30)=0.44; P>0.60 
(horizontal wire test), n=9, 10, 8, and 7 mice, for vehicle, and 10, 30, and 100 mg/kg DZP. All data points are 
mean±SEM. 
 
Our findings on the contribution of α1, α2, and α3GABAARs to sedation, anxiolysis, and 
muscle relaxation confirm previous studies using single GABAAR point mutated mice 
(Rudolph et al., 1999; Löw et al., 2000; Crestani et al., 2001). The results from our 
experiments with triple point mutated mice on motor coordination however differ from those 
obtained with single point mutated mice (Rudolph et al., 1999; Löw et al., 2000). This 
discrepancy may arise from the involvement of mixed GABAARs containing α1 and α3 
subunits. We therefore tested whether motor coordination would also be impaired by TP003, 
an α3GABAAR selective BDZ site agonist (Dias et al., 2005). Two hours after treatment with 
TP003 (10 mg/kg, p.o.), the time to fall off the rod was similarly decreased in wt and RRHR 
mice (by 43.9 ± 10.2%, paired t-test P < 0.05, n = 5, in wt mice, and by 38.5 ± 6.4, n = 5, P < 
0.05) while HHRH and vehicle treated wt mice showed no impairment (0.7 ± 12.0%, n = 5, P 
= 0.91, and -4.7±9.2%, n = 5, P = 0.59). 
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Liability to tolerance development 
Another major limitation of classical BDZs is their liability to tolerance development (i.e. the 
loss activity during prolonged use). We tested whether this tolerance would also occur for the 
antihyperalgesic actions of BDZs and whether it could be prevented by selectively targeting 
α2GABAARs. To this end, we applied again CCI surgery and treated mice of the different 
strains for 9 consecutive days with 10 mg/kg DZP or vehicle p.o. once daily. On the 10th day, 
both groups of mice were split into two subgroups, treated with either 10 mg/kg DZP or 
vehicle, and mechanical hypersensitivity was monitored for 2 hours after drug application. 
We first did this experiment in single α1 point-mutated (RHHH) mice to avoid confounding 
sedation (Fig. 5 A,D). While DZP-naïve mice responded with an almost complete reversal of 
hyperalgesia, mice chronically pre-treated with DZP showed no antihyperalgesic response. 
We then performed this experiment in triple point-mutated RHRR mice with only α2 BDZ-
sensitive GABAARs and found that these mice were completely protected from tolerance 
development (Fig. 5 B,E). In the latter experiment, the antihyperalgesic response was 
generally lower than in α1 point-mutated (RHHH) mice. We therefore repeated the first 
experiment with a lower dose of DZP (3 mg/kg) to exclude the possibility that the absence of 
tolerance in the RHRR mice was due to a smaller DZP effect. With this lower dose, complete 
tolerance still developed in RHHH mice (Fig. 5 C,D). These experiments indicate that 
activity at α3 or α5GABAARs was necessary to induce antihyperalgesic tolerance. We 
therefore tested double point-mutated mice in which α3GABAARs or α5GABAARs were left 
BDZ-sensitive in addition to α2GABAARs (RHHR and RHRH mice). Complete tolerance 
developed in RHHR mice, but not in RHRH mice, indicating that activity at α3GABAARs 
was necessary for induction of antihyperalgesic tolerance in mutated mice (Fig. 5E). In this 
set of experiments, we finally tested whether the same subtype-dependence would also be 
found for tolerance against α2GABAAR-mediated anxiolysis (Fig. 5F). Unlike 
antihyperalgesic tolerance, anxiolytic tolerance, measured as increased locomotor activity in 
the open field, still developed in RHRR mice. This dissociation suggests that tolerance 
development against antihyperalgesia is not a receptor or cell autonomous process (Jacob et 
al., 2012) but rather occurs at the circuit level.  
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Figure 5. Tolerance liability against the antihyperalgesic effects of DZP.  
Starting on day 5 after CCI surgery, mice were treated with DZP or vehicle once daily for 9 consecutive days. 
On day 10, mice were given either DZP or vehicle, and antihyperalgesic effects were measured for 2 hours. (A) 
Complete loss of antihyperalgesic activity was observed after 9-day DZP treatment (10 mg/kg, p.o.) in RHHH 
mice. (B) Same as (A) but RHRR triple point-mutated mice. These mice were completely protected from 
tolerance development against DZP-induced antihyperalgesia. (C) Same as (A) but lower dose of DZP (3 
mg/kg, p.o.). Tolerance in RHHH mice still developed at a lower dose of DZP, which induced an 
antihyperalgesic effect similar to that of 10 mg/kg in RHRR mice. (D) Statistical comparison. Two-way 
ANOVA for the interaction pretreatment x acute treatment (F(3,25)=32.5 (n=5, 8, 7, and 8 mice for veh/veh, 
veh/DZP, DZP/veh, and DZP/DZP groups, respectively); F(3,25)=0.014 (n=7, 8, 7, and 6); F(3,24)=5.97 (n=8, 
7, 7, and 6), for data shown in A, B, and C). Maximum antihyperalgesic activity was calculated for the interval 
between 80 and 120 min after DZP administration. (E) Double GABAAR point-mutated mice (RHHR and 
RHRH), in which α3GABAAR or α5GABAAR were left BDZ-sensitive in addition to α2GABAAR. Tolerance 
development required the additional presence of DZP-sensitive α3GABAAR. Two-way ANOVA for the 
interaction pretreatment x acute treatment. RHHR mice: F(3,22)=22.1 (n=6, 6, 7, and 6 mice for for veh/veh, 
veh/DZP, DZP/veh, and DZP/DZP groups, respectively); RHRH mice: F(3,21)=0 (n=6 for all groups). (F) 
Unlike antihyperalgesic effects, anxiolytic effects of DZP were still susceptible to tolerance development in 
RHRR mice after 9-day treatment with DZP (10 mg/kg, p.o.). Two-way ANOVA F(3,26)=28.3 (n=8, 7, 7, and 
7) for the interaction pretreatment x acute treatment. ***, P=0.001; *, P=0.05. All data points are mean±SEM. 
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Why classical BDZs lack clinically relevant analgesic properties 
Our present results and previous pain studies employing subtype-selective BDZ site agonists 
in rodents (Knabl et al., 2008; Di Lio et al., 2011; Knabl et al., 2009; Hofmann et al., 2012; 
Nickolls et al., 2011; Munro et al., 2008) contrast with the lack of a clear analgesic or 
antihyperalgesic action of classical BDZs in human patients (Richards et al., 2012; Corrigan 
et al., 2012). Apart from species differences and differences between disease models and 
actual disease in human patients, we found one possible explanation particularly worth 
studying. The doses and the degrees of receptor activation required for a relevant effect might 
be significantly higher in case of antihyperalgesia than of sedation. As a consequence, 
antihyperalgesia would occur in patients only at doses already inducing strong sedation. 
The availability of the triple point-mutated mice allowed us to directly compare the doses and 
levels of receptor occupancy at the relevant GABAAR subtypes and sites. For these 
experiments, we chose midazolam (MDZ) as a second classical BDZ in addition to DZP. 
First, we determined for both drugs their α2/α1 selectivity profiles in electrophysiological 
experiments on recombinant GABAARs. As expected we found that DZP potentiated 
α1/β2/γ2 and α2/β3/γ2 GABAARs with similar efficacy and potency (Fig. 6A and Tab. 3).  
By contrast, MDZ potentiated α1/β2/γ2 GABAARs more than twice as much as α2/β3/γ2 
GABAARs (Fig. 6B and Tab. 3). We then verified that the H → R point mutation blocked not 
only DZP effects but also MDZ binding and GABAAR potentiation (Fig. 6C,D; see also Tan 
et al., 2010). Next, we compared the dose-dependency of DZP- and MDZ-induced 
antihyperalgesia in mice with only α2 BDZ-sensitive GABAARs (RHRR mice) with that of 
DZP- and MDZ-induced sedation in mice with only α1 BDZ-sensitive GABAARs (HRRR 
mice). We found that half maximal sedation occurred already at a doses of 0.33 ± 0.05 mg/kg 
and of 0.52 ± 0.11 mg/kg (mean ± SD) for DZP and MDZ, respectively, while half maximal 
antihyperalgesia required 8 ± 6 mg/kg (DZP) and 10.4 ± 2.0 mg/kg (MDZ). A rightward shift 
of the response curve was also observed when the degrees of receptor occupancy required for 
antihyperalgesia and for sedation were compared. Half maximal sedation was reached when 
DZP had bound 47 ± 6% brain α1GABAARs, while half maximal antihyperalgesia required 
71 ± 2% occupancy at spinal α2GABAARs. In case of MDZ, the required receptor 
occupancies were even further apart (24 ± 2% of brain α1GABAARs and 71 ± 2% of spinal 
α2GABAARs) consistent with the even less favorable α2/α1 selectivity ratio of MDZ.  
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These data indicate that, when applied to wt mice, the DZP and MDZ doses needed for half 
maximal antihyperalgesia induce an almost complete (about 95%) reduction in locomotor 
activity, while at non-sedative doses both BDZs would not induce significant 
antihyperalgesia. Dose-limiting sedation is therefore the most likely reason for the absence of 
a relevant antihyperalgesic activity of classical, non-selective BDZs in human patients. 
 
Figure 6. Activity of DZP and MDZ at α1 and α2GABAARs, and PK/PD modelling.  
(A,B) Potentiation of recombinant α1β2γ2 and α2β3γ2 GABAAR currents by 1 µM DZP (A) and 1 µM MDZ 
(B). GABA concentration was EC5 (5 µM for α1β2γ2 and 2 µM for α2β3γ2). n=6 for both drugs and all 
concentrations. Scales bars, 200 pA, 2 s. (C,D) The H101R mutation prevented potentiation of α1β2γ2 
GABAAR currents by MDZ (**, P<0.01, n=5, unpaired t-test) (C) and binding of MDZ to α1β2γ2 GABAARs 
(n=6 for all concentrations in wt and mutated receptors) (D). (E-H) α1GABAAR-mediated sedation and 
α2GABAAR-mediated antihyperalgesia by DZP and MDZ. Sedation (black symbols) in HRRR mice was 
assessed in the open field test and expressed as percent maximum possible effect determined from the reduction 
in activity compared to vehicle-treated mice of the same genotype. Antihyperalgesia (red symbols) in RHRR 
mice was determined as the increase in mechanical withdrawal thresholds compared to pre-drug values one 
week after CCI surgery. (E,F) Dose-response relationships. Data were fitted to Hill’s equation with baseline 
fixed at 0. Sedation and antihyperalgesia were determined between 15 and 90 min after oral DZP (E) or between 
15 and 60 min after oral MDZ (F). Mice were killed immediately afterwards (i.e. at the time point of maximal 
effects), and brains and spinal cords were removed for further analyses. (G,H) Dependence on receptor 
occupancy (RO). (G) Sedation versus RO in brains of HRRR mice treated with DZP (0.03, 0.1, 0.3, 1, 3, 10, 30 
mg/kg, n=6 mice for all doses). Antihyperalgesia versus RO in lumbar spinal cords of RHRR mice treated with 
0.1, 1, 3, 10, or 30 mg/kg DZP, n=6 mice for all doses. (H) Same as G but MDZ. Sedation 0.1 (n=6 mice), 0.3 
(7), 0.5 (7), 1.0 (7), 3 (6), 10 (4) mg/kg. Antihyperalgesia 0.1 (n=3), 0.3 (5), 1.0 (9), 3 (8), 5 (7), and 10 (7) 
mg/kg MDZ. Data were fitted to sigmoidal functions. Data shown in E and G (on DZP) and in F and H (on 
MDZ) are from the same two groups of mice. All data points are mean±SEM. 
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Table 3: PK/PD parameters1 of DZP and MDZ  
 DZP MDZ 
 a1/b2/g2 a2/b3/g2 a1/b2/g2 a2/b3/g2 
EC50 (µM) 0.081 ± 0.020 0.15 ± 0.04 0.17 ± 0.18 0.092 ± 0.019 
Emax (% pot IGABA) 91.6 ± 7.7 103 ± 11 235 ± 43 75.8 ± 4.7 
nH 1.50 ± 0.60 1.20 ± 0.35 0.73 ± 0.26 1.23 ± 0.29 
a2/a1 selectivity2  1.25 0.32 
 sedation analgesia sedation analgesia 
ED50 (mg/kg) 0.33 ± 0.05 7.6 ± 0.6 0.52 ± 0.11 10.4 ± 2.0 
Emax (% MPE) 93.6 ± 4.5 100 (fixed) 92.2 ± 10.4 100 (fixed) 
nH 2.0 ± 0.64 0.75 ± 0.19 2.28 ± 0.98 1.42 ± 0.40 
ED50 (sedation/analgesia) 0.043 0.050 
 sedation analgesia sedation analgesia 
RO50 (%) 46.9 ± 5.5 70.9 ± 1.7 23.7 ± 2.2 76.5 ± 1.8 
Emax 97.9 ± 7.1 100 (fixed) 94.7 ± 11.8 100 (fixed) 
rate 14.1 ± 4.1 14.9 ± 2.0 4.14 ± 2.10 5.01 ± 2.11 
RO50 (sedation/analgesia) 0.66 0.31 
 
1 values are mean±SD 
2 Emax (a2/b3/g2) / Emax (a1/b2/g2) 
For number of mice per group see figure 6. 
 
 
Discussion  
In the present study we have employed triple GABAAR point-mutated mice to characterize 
the pharmacological actions expected from yet-to-be-developed subtype-selective BDZ 
binding site agonists. The present study can be viewed as a “restriction-of-function” approach 
(“what effect of DZP remains when only a single GABAAR subtype is targeted?”) as opposed 
to previous loss-of-function studies in single GABAAR point-mutated mice (“which effects of 
DZP are lost or reduced when activity at one GABAAR subtype is abolished compared to 
DZP-treated wt mice?”). With respect to sedation, anxiolysis, and the muscle relaxant action, 
the present study confirms previous results obtained with single point-mutated mice: sedative 
actions of BDZs occur through α1GABAAR (McKernan et al., 2000; Rudolph et al., 1999), 
anxiolytic effects through α2GABAARs (Löw et al., 2000), and muscle relaxation through α2 
and α3GABAAR (Crestani et al., 2001).  
Discrepancies between results from restriction-of-function and loss-of-function approaches 
were observed for impairment of motor coordination. Our study shows that undesired 
impairment of motor coordination is caused by DZP in HRRR and RRHR mice (i.e. it is 
evoked when either α1 or α3GABAARs are specifically targeted), while previous reports in 
the respective single point-mutated mice failed to provide evidence for an involvement of 
these GABAAR subtypes (Rudolph et al., 1999; Löw et al., 2000). This discrepancy is 
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consistent with the idea that DZP impairs motor coordination through mixed GABAARs 
containing an α1 and an α3 subunit (α1/α3GABAARs). Immunohistochemical analyses have 
shown that co-expression of α1 and α3 GABAAR subunits occurs in subsets of central 
neurons (Fritschy & Möhler, 1995; Bohlhalter et al., 1996), and biochemical data have 
provided direct evidence for the presence of different α subunits within the same GABAAR 
complex (Benke et al., 2004). In particular α3 containing GABAARs occur mainly as mixed 
α1/α3GABAARs (Araujo et al., 1996; Benke et al., 2004). Furthermore, biochemical data 
also suggest that in mixed GABAARs with one point-mutated α subunit the non-point-
mutated (wt) subunit has a higher probability for interaction with the γ2 subunit than the 
point-mutated α subunit (Benke et al., 2004; Balic et al., 2009). Results from loss-of-function 
analysis in single point-mutated mice and from restriction-of-function analyses in triple 
point-mutated mice should therefore be seen as lower and upper limits for the contribution of 
a given GABAAR subtype to an in vivo drug action. Conversely, the lack of sedation in α1 
point-mutated mice (McKernan et al., 2000; Rudolph et al., 1999) and of anxiolysis in α2 
point-mutated mice (Löw et al., 2000) suggests that these actions occur through GABAARs 
with only a single type of α subunit. In line with this conclusion is that the majority of 
GABAARs in the brain are pure α1GABAARs (α1/α1GABAARs) (Benke et al., 2004). 
Similarly, BDZ-mediated anxiolysis occurs through pure α2GABAARs with α2/α2GABAARs 
being the single most prevalent isoform of α2 containing GABAARs at supraspinal sites 
(Benke et al., 2004).  
As demonstrated by our autoradiography experiments (compare Fig. 1 D,E), mixed 
GABAARs make up the vast majority of GABAARs in the spinal cord. Following the model 
described above, one would expect that in case of mixed GABAARs the single point mutation 
approach would yield smaller effects than the triple point mutation strategy. For instance, in 
case of an αx/αyGABAAR neither the αx single point mutation nor the αy single point 
mutation would abolish BDZ sensitivity, but both triple point-mutated mice with only αx or 
only αy remaining BDZ sensitive would yield full behavioral effects. Results for 
antihyperalgesia obtained in the present study were consistent with a contribution of mixed 
GABAARs to antihyperalgesia. For all three contributing α subunits, the loss-of-function 
obtained through point mutation of one α subunit was smaller than the restriction-of-function 
in the respective triple point-mutated mouse. The discrepancies were particularly large for α3 
in mechanical sensitization and for α5 in heat hyperalgesia suggesting that these effects occur 
mainly through mixed GABAARs. Importantly, the rank orders of antihyperalgesic efficacy 
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were the same for the restriction-of-function and loss-of-function approaches with α2>α5>α3 
for mechanical sensitization and α2>α3>α5 for heat hyperalgesia and chemical nociception. 
The same rank order of efficacies has also been reported previously for antihyperalgesia 
using local spinal injections in single GABAAR point mutated mice (Knabl et al., 2008). Our 
present results therefore corroborate the critical importance of α2GABAARs as targets for 
antihyperalgesia.  
Our experiments on the quadruple point-mutated mice indicate that antihyperalgesia, 
anxiolysis, muscle relaxation and impairment of motor coordination occur through the high 
affinity BDZ binding site formed by the α/γ interface. Among the DZP actions assessed here, 
only sedation by high doses of DZP occurred in quadruple point-mutated mice. This result is 
consistent with previous electrophysiological data, which suggested the presence of a low-
affinity BDZ binding site in α1GABAARs contributing to the anesthetic actions of BDZs 
(Walters et al., 2000).  
Most BDZ effects quickly diminish during prolonged treatment (i.e. they undergo fast 
tolerance development). In the present study, we show that this is also the case for 
antihyperalgesia. Previous studies with the non-sedative BDZ site ligands L-838,417 and HZ-
166 showed that these compounds have strongly reduced liabilities to tolerance development 
(Knabl et al., 2008; Di Lio et al., 2011; Hofmann et al., 2012). It has however not been 
possible to attribute this reduced tolerance to generally reduced agonistic activity or to 
improved subtype specificity. Our present study shows that tolerance can be avoided when 
only α2GABAARs are targeted, even with compounds that exert full agonistic activity. 
Additional experiments in RHRH and RHHR mice exclude α5GABAARs and suggest that 
activity at α3GABAARs is required for tolerance induction. However, because all these 
experiments were done in mice carrying the H → R point mutation in the α1 subunit, we 
cannot exclude that tolerance occurs through mixed α1/α3GABAARs, which in the wt 
situation may exhibit an α1 pharmacology. Such a scenario would explain why compounds 
with activity at α3GABAARs but absent or reduced activity at α1GABAARs lack liability to 
tolerance (Knabl et al., 2008; Di Lio et al., 2011; Hofmann et al., 2012). Interestingly, 
tolerance against the anxiolytic action of DZP was retained in triple point-mutated RHRR 
mice with only α2GABAARs remaining BDZ-sensitive. This difference suggests that 
tolerance development against the different BDZ effects involves activity at distinct subunits 
and possibly different mechanisms. Cell or receptor autonomous processes, which have been 
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proposed for the desensitization of hippocampal α2GABAARs (Jacob et al., 2012), are 
unlikely to be responsible for the tolerance against antihyperalgesia.  
Addictive (reinforcing) properties of classical BDZs are another area of concern that has not 
been addressed in the present study. Reduced BDZ-induced reward facilitation has been 
reported in mice carrying the H → R point mutation in either the α1, α2, or α3GABAAR 
subunits (Engin et al., 2014; Reynolds et al., 2012). Preference for MDZ in a two-bottle 
choice paradigm was absent in α1 (Corrigan et al., 2012; Engin et al., 2014) and α2 point-
mutated mice (Engin et al., 2014), suggesting that the simultaneous positive modulation of 
both the α1 and α2GABAAR are required for reinforcement. Tan et al. (ref. 32) reported that 
α1GABAARs on GABAergic neurons in the ventral tegmental area (VTA) are required for 
MDZ-induced neuronal plasticity strengthening glutamatergic excitation in the VTA. These 
findings suggest that activity at more than one GABAAR subtype is necessary for BDZ 
reinforcement. α2-selective BDZ site agonists might therefore be largely devoid of addictive 
properties. 
Previous studies have provided evidence that activation of supraspinal GABAARs might 
enhance pain and counteract spinal antihyperalgesia, e.g. through the inhibition of descending 
antinociceptive fiber tracts (Tatsuo et al., 1999; Luger et al., 1995; Harris & Westbrook, 
1995). In our study, we did not observe any pronociceptive actions of systemically 
administered DZP. If such pronociceptive actions were relevant in the pain models used here, 
they would occur through α1GABAARs whose functions in nociception were not addressed 
in the present study. Any such effects would be avoided by α1-sparing BDZ site agonists.  
The availability of the triple GABAAR point-mutated mice permitted a direct 
pharmacokinetic/pharmacodynamic comparison of α1-mediated sedation and α2-mediated 
antihyperalgesia in the absence of confounding behavioral effects from other GABAAR 
subtypes. In case of DZP, ED50 values for sedation and antihyperalgesia differed by a factor 
of more than 20, and a 50% higher degree of receptor occupancy was needed for α2-mediated 
antihyperalgesia compared to α1-mediated sedation. New subtype-selective agents will 
therefore have to have a high degree of α2 over α1 selectivity in order to achieve clinically 
relevant antihyperalgesia in the absence of sedation. These data also indicate that dose-
limiting sedation most likely underlies the lack of clinically relevant antihyperalgesic effects 
of presently used (non-selective) BDZs. This is consistent with a recent clinical study in 
human volunteers showing weak antihyperalgesic effects at doses that caused only mild 
sedation (Vuilleumier et al., 2013). 
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Which GABAAR subtype should be targeted for an optimal benefit-risk ratio in pain 
treatment? Both the present restriction-of-function and loss-of-function experiments on 
systemic BDZ administration and previous experiments with local spinal injections and 
single GABAAR point-mutated mice (Knabl et al., 2008) attribute the highest 
antihyperalgesic efficacy to α2GABAARs. The present study has shown that adding activity 
at α3GABAARs or α5GABAARs increases antihyperalgesic efficacy only moderately or not 
at all. Because it is at present not known how the different mixed GABAARs respond to 
subtype-selective agents, a conservative prediction should be made on the basis of the results 
obtained from triple point-mutated mice. These experiments indicate that sedation is 
exclusively due to activation α1GABAARs, which is also consistent with studies using the 
subtype selective agonist TPA023B that completely lacks agonistic activity at α1GABAARs 
as well as sedation in humans (Atack et al., 2011). The present experiments also showed that 
impaired motor coordination involves α1GABARs and/or α3GABAARs. None of the 
undesired effects investigated in the present study could be attributed to α5GABAARs. 
However, cognitive impairment by non-selective BDZ likely originates from activity at 
α5GABAARs, as α5GABAAR-selective inverse agonists enhance cognitive capabilities 
(Dawson et al., 2006). Subtype-selective BDZ agonists targeting only α2GABAARs should 
therefore have the best benefit-risk ratio. They will produce pronounced antihyperalgesia in 
the absence of sedation and will not interfere with motor coordination and should not lose 
antihyperalgesic activity during prolonged treatment. They will however have anxiolytic 
properties (at least during the beginning of the treatment) and muscle relaxant effects. Both of 
these actions may be beneficial in chronic pain patients. Because the side-effects studied here 
are relevant for other indications, we expect that our present findings will benefit not only the 
development of innovative subtype-selective BDZs as analgesics but also as drugs for the 
treatment of several prevalent psychiatric diseases (Rudolph & Möhler, 2014). 
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Methods 
Mice 
Experiments were performed in wt mice, and in homozygous single, double, triple and 
quadruple (H→R) GABAAR point-mutated mice, i.e. in mice expressing different 
combinations of BDZ-sensitive and BDZ-insensitive GABAAR α subunits. All mice were of 
the same genetic background (129X1/SvJ). Double, triple and quadruple point-mutated mice 
were generated by cross breeding single point-mutated mice described earlier (Rudolph et al., 
1999; Löw et al., 2000; Crestani et al., 2002). 
Autoradiography 
The distribution of BDZ-sensitive GABAAR subtypes in the lumbar spinal cord was 
examined in 16 µm thick horizontal sections, which were cut from fresh-frozen spinal cords. 
Sections were incubated with 5 nM [3H]flumazenil (50 Ci/mmol) or 9 nM [3H]Ro15-4513 
(22.7 Ci/mmol) diluted in 50 mM Tris pH 7.4 for 120 min on ice. After washing three times 
for 20 s in ice-cold buffer, sections were dried and exposed along with [3H]-standards to a 
tritium-sensitive phosphoimaging screen (Cyclone Storage Phosphor Screen, Perkin Elmer). 
Quantification was done using the Optiquant software (Perkin Elmer). Non-specific binding 
was assessed by co-incubating 10 µM clonazepam ([3H]flumazenil binding) or 10 µM 
flumazenil ([3H]Ro15-4513 binding).  
Immunohistochemistry 
The localization of GABAAR subunits was visualized on 40 µm thick lumbar spinal cord 
cryosections by DAB immunoperoxidase staining on sections from aCSF perfused mice 
postfixed for 90 min in 4% PFA (without picric acid) (Paul et al., 2012). Antibodies were 
home-made subunit-specific antisera (Paul et al., 2012). Final dilutions were 1:20,000 (α1), 
1:1,000 (α2), 1:10,000 (α3), 1:3,000 (α5) and 1:10,000 (γ2). Images were taken with a bright 
field light microscope connected to a digital camera, processed with AxioVision Rel. 4.5 
software where an intensity-gradient false-color filter was applied.  
Behavioral experiments 
All behavioral experiments were performed in 7 – 12 week old female and male mice. Care 
was taken to ensure equal numbers of female and male mice. All behavioral experiments 
were made by a male experimenter, blinded either to the genotype of the mice or to their 
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treatment with drug or vehicle. Permission for animal experiments was obtained from the 
Veterinäramt des Kantons Zürich (license numbers 135/2009 and 126/2012). 
DZP (suspended in 0.9% saline, 1% Tween80) and MDZ (dissolved in 0.9% saline pH 3.0) 
were applied orally in all experiments. HZ-166 (suspended in 0.5% methyl cellulose) was 
given intraperitoneally (i.p.). 
Neuropathic pain was evoked through CCI (Bennett & Xie, 1988) of the left sciatic nerve 
proximal to the trifurcation with three loose (5-0 silk) ligatures. Mice, which showed signs of 
paralysis or which did not develop significant hypersensitivity, were excluded from 
subsequent experiments. Effects of DZP and MDZ (p.o. in 0.9% saline, 1% Tween80) on 
thermal and mechanical hyperalgesia were assessed one week after surgery. Heat 
hyperalgesia was quantified as the change in the latency of paw withdrawal evoked by 
exposure of the plantar side of one hindpaw to a defined radiant heat stimulus. Mechanical 
hyperalgesia was assessed with electronic von Frey filament #7 (IITC, Woodland Hills, CA). 
Three to four measurements were made for each time point and animal for both heat and 
mechanical hyperalgesia. Percent maximal possible effect (%MPE) was calculated as 
follows:  
%MPE(t) = (E(t)-Epredrug))/(EpreCCI-Epredrug); E(t), paw withdrawal thresholds or latency at 
time point t. Epredrug, E after CCI surgery but before DZP application; EpreCCI, E baseline 
before CCI surgery.  
Formalin (4 %, 20 µl) was injected subcutaneously into the plantar surface of the left 
hindpaw. Flinches and licks of the injected paw were counted for one hour in 5 min intervals 
starting immediately after formalin injection. DZP was administered p.o. 60 min before 
formalin. 
Locomotor activity was measured in an open field arena (10 cm diameter) equipped with four 
pairs of light beams and photosensors. Mice were placed into the arena 75 min before DZP 
application. Locomotor activity was analyzed for the time interval between 20 and 165 min 
after DZP administration. 
Motor control was assessed with a rotarod accelerating from 4 rpm to 40 rpm within 5 min. 
Sixty min after DZP administration mice were placed onto the rotarod. Five measurements 
were taken per mouse. 
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To assess muscle relaxation, mice were placed with their forepaws onto a metal horizontal 
wire placed 20 cm above ground. Successes and failures to grab the wire with at least one 
hindpaw were recorded between 60 and 180 min after DZP administration.  
Electrophysiology 
The effects of DZP and MDZ on currents through recombinant GABAARs were studied in 
HEK293 cells (ATCC) transiently expressing GABAARs. HEK293 cells were transfected 
using lipofectamine LTX (Paul et al., 2014). To ensure expression of the γ2 subunit (required 
for modulation of GABAARs by BDZs) in all recorded cells, we transfected cells with a 
plasmid expressing the γ2 subunit plus eGFP from an IRES, and only selected eGFP-positive 
cells for recordings. The transfection mixture contained (in µg): 1 α1, 1 β2, 3 γ2/eGFP (used 
as a marker of successful transfection) or 1 α2, 1 β3, 3 γ2/eGFP. Recordings were made 18 – 
36 hrs after transfection. Whole-cell patch-clamp recordings of GABA-evoked currents were 
made at room temperature (20 – 24°C) and at a holding potential of -60 mV. Recording 
electrodes were filled with solution containing (in mM): 120 CsCl, 10 EGTA, 10 HEPES (pH 
7.40), 4 MgCl2, 0.5 GTP and 2 ATP. The external solution contained (in mM): 150 NaCl, 10 
KCl, 2.0 CaCl2, 1.0 MgCl2, 10 HEPES (pH 7.4), and 10 glucose. GABA was applied to the 
recorded cell using a manually controlled pulse (4 - 6 s) of a low sub-saturating GABA 
concentration (EC5). EC5 values of GABA were determined for wt α1β2γ2, wt α2β3γ2 and 
mutant α1(H101R)β2γ2 receptors. EC50 values and Hill coefficients (nH) were obtained from 
fits of normalized concentration–response curves to the equation IGABA = Imax [GABA]nH / 
([GABA]nH + [EC50]nH). Imax was determined as the average maximal current elicited by a 
concentration of 1 mM GABA. DZP and MDZ dissolved in DMSO and subsequently diluted 
with recording solution were co-applied together with GABA without preincubation. 
[3H]Ro 15-4513 binding assay to recombinant GABAARs 
HEK293 cells were maintained in DMEM supplemented with 10% FBS and seeded to a 
density of 500,000 cells onto poly-lysine-coated 100 mm culture dishes one day before 
transfection. Cells were transfected with plasmids containing the subunit combination α1β2γ2 
or α1(H101R)β2γ2 (7 mg total DNA, ratio 1:1:2) using jetPEI transfection reagent (Polyplus-
transfection). Twenty-four hours after transfection, HEK293 cells were harvested in PBS. 
HEK293 cells were homogenized in 10 mM Tris pH 7.5, protease inhibitor cocktail 
(complete Mini, Roche Applied Science). Aliquots of the homogenate prepared from 
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HEK293 cells expressing the α1β2γ2 or α1(H101R)β2γ2 subunit combination were incubated 
with increasing concentrations of MDZ and 6.3 nM [3H]Ro15-4513 (22.7 Ci/mmol, 
PerkinElmer) in a total volume of 200 µl for 90 min on ice. Subsequently, the samples were 
filtered onto glass fiber filters using a 12-channnel semiautomated cell harvester (Scatron) 
and washed with ice-cold buffer (10 mM Tris-HCl pH 7.4). Non-specific [3H]Ro15-4513 
binding was measured using 10 µM flumazenil. The radioactivity of the filters was 
determined by liquid scintillation counting using a Tricarb 2500 liquid scintillation analyzer.  
Receptor occupancy 
Mice were killed immediately after completion of the behavioral tests, i.e. 90 min after DZP 
administration and 60 min after MDZ administration. Brains and spinal cords were removed 
and kept frozen until further processing. Percentage of receptors occupied by DZP or MDZ 
was determined ex vivo with [3H]flumazenil as radioligand (Li et al., 2006). Frozen brains or 
lumbar spinal cords were rapidly homogenized in 20 volumes 10 mM Tris pH 7.4, 100 mM 
KCl, and 100 µl aliquots were immediately added to 400 µl ice-cold buffer containing 4 nM 
[3H]flumazenil. After 30 s of incubation, samples were filtered onto Whatman GF/C glass-
fiber filters and washed 3 times with 4 ml ice-cold buffer. Radioactivity retained on the filters 
was determined by scintillation counting. To determine non-specific [3H]flumazenil binding, 
mice were used that had been injected i.p. with 5 mg/kg bretazenil (dissolved in PEG300) to 
fully occupy all BDZ-binding sites (100% receptor occupancy (Li et al., 2006)). 
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Abstract  
Data obtained in genetically modified mice suggest that benzodiazepine-site ligands with 
improved selectivity for α2-subtype GABAA receptors are potentially useful in the treatment 
of pathological pain syndromes. Compounds available for preclinical tests support that this 
concept works in rodents but none of these compounds has so far been approved for use in 
humans precluding proof-of-concept studies in human volunteers or pain patients. We have 
recently proposed that N-desmethyl clobazam (NDMC), the main metabolite of clobazam 
(CBZ), contributes to the antihyperalgesia observed in mice after administration of CBZ. In 
the present study we compared the in vitro GABAAR subtype specificity of NDMC and CBZ 
and compared their propensity to sedation. We found that NDMC has higher efficacy at α2-
GABAAR and weaker sedative effects than CBZ. NDMC exerted significant antihyperalgesic 
effects in the chronic constriction model of neuropathic pain at doses between 3 and 30 
mg/kg body weight. At 30 mg/kg NDMC completely reversed heat and mechanical 
hyperalgesia. This antihyperalgesic response was completely lost in quadruple point mutated 
mice in which all high-affinity benzodiazepine sites had been rendered insensitive. At doses 
up to 30 mg/kg NDMC did not cause a significant reduction in muscle strength and did not 
impair motor coordination. Our data suggest that NDMC might be a useful tool compound to 
assess potential analgesic or antihyperalgesic effects of improved benzodiazepine site ligands 
in human volunteers or pain patients. 
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Introduction 
Chronic pain is a medical condition that is often resistant to currently available 
pharmacotherapy. In particular neuropathic pain does not respond well to the majority of 
conventional analgesics and drugs that are effective often elicit intolerable side-effects 
prompting for the discontinuation of treatment. The identification of novel drug targets based 
on disease mechanisms and the developments of new analgesic drugs targeting the 
mechanisms of pain pathology should offer the opportunity to improve the current situation.  
Many chronic pain states, at least in animal models, are accompanied by diminished synaptic 
inhibition at the spinal cord level (Zeilhofer et al., 2012). Their potential relevance as a 
disease mechanism is supported by rodent experiments showing that a blockade of spinal 
GABA and glycine receptors induces pain behaviors (Beyer et al., 1985; Roberts et al., 1986; 
Sivilotti & Woolf, 1994). Conversely, spinally applied diazepam, which enhances 
GABAergic inhibition, reverses pathologically increased pain sensitivity in rodent models of 
chronic inflammatory and neuropathic pain (Knabl et al., 2008a). This action occurs through 
the α2-subtype of GABAA receptors (α2-GABAARs; (Knabl et al., 2008b)). Genetically 
mutated (triple GABAA receptor point mutated mice) in which all GABAAR subtypes had 
been rendered diazepam (DZP)-insensitive except for the α2-GABAARs show pronounced 
antihyperalgesia in response to systemic DZP administration but do not exhibit signs of 
sedation or impaired motor coordination (Ralvenius et al., 2015). The observation that the 
different desired and unwanted effects of classical benzodiazepines are mediated by distinct 
GABAAR subtypes has stimulated the development of benzodiazepine site agonists with 
improved subtype selectivity (Rudolph & Knoflach, 2011). Because many of the typical side 
effects of classical benzodiazepines such as sedation, addiction, and motor impairment 
depend on activation of α1-GABAARs (Rudolph et al., 1999; Tan et al., 2010; Ralvenius et 
al., 2015) most efforts aimed at the development of benzodiazepine site agonists with reduced 
activity at α1-GABAARs. Such compounds were also evaluated in different rodent pain 
models (Knabl et al., 2008b; Knabl et al., 2009; Munro et al., 2009; Di Lio et al., 2011; 
Nickolls et al., 2011; Hofmann et al., 2012; Reichl et al., 2012; Paul et al., 2014), reviewed in 
(Zeilhofer et al., 2012). These studies have provided proof-of-concept evidence that the 
results obtained in genetically modified mice translate into antihyperalgesic efficacy of novel 
benzodiazepine site agonists with improved subtype selectivity. 
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However, given recent concerns about the predictive value of animal and, in particular, 
rodent pain models in pain research (Tappe-Theodor & Kuner, 2014), it appears important to 
obtain proof-of-concept data on the translatability of these findings to human pain patients. 
Classical benzodiazepine site agonists such as clonazepam and clobazam have been shown to 
exert weak analgesic effects at mildly sedating doses (Vuilleumier et al., 2013; Besson et al., 
2015). Our recent preclinical study comparing antihyperalgesic and sedative effects of DZP 
and midazolam in genetically modified mice suggests that dose limiting sedation is the major 
reason for the absence of clinically relevant analgesic effects in humans (Ralvenius et al., 
2015). However, based on these data species differences cannot be excluded. None of the 
recently developed benzodiazepine-site ligands with improved selectivity for α2-GABAARs 
has so far been approved for use in human patients (Rudolph & Knoflach, 2011). Therefore 
these compounds are currently not readily available for proof-of-concept studies in human 
patients. We therefore evaluated alternative possibilities. In a previous preclinical 
pharmacokinetic/ pharmacodynamic (PK/PD) study on possible antihyperalgesic effects of 
clobazam, a clinically used benzodiazepine with less sedative effects, we found that 
antihyperalgesic effects correlated better with plasma levels of the main clobazam metabolite 
N-desmethyl clobazam (NDMC) than with plasma levels of the parent compound (Besson et 
al., 2013). In the present study we have systematically evaluated the subtype selectivity of 
NDMC in human recombinant GABAARs, and its antihyperalgesic effects in a mouse model 
of neuropathic pain and for different potential unwanted effects. We found that NDMC has a 
better α2/α1-GABAAR selectivity-profile than clobazam and better than the canonical 
benzodiazepine site agonist DZP. It evoked profound antihyperalgesia at doses, which did not 
cause obvious sedation, muscle relaxation or impairment of motor coordination in mice. 
Because NDMC is a naturally occurring active metabolite of CBZ in humans, it should be 
devoid of new serious reactions or toxicity in humans. It therefore appears as a suitable tool 
compound to assess potential antihyperalgesic efficacy of benzodiazepine site agonists in 
humans. 
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Material and Methods 
Electrophysiology 
The effects of DZP, CBZ and NMDC on currents through recombinant GABAARs were 
studied in HEK293 cells (ATCC) transiently expressing rat GABAARs. HEK293 cells were 
transfected using lipofectamine LTX 46 (invitrogen). To ensure expression of the γ2 subunit 
(required for modulation of GABAARs by BDZs) in all recorded cells, we transfected cells 
with a plasmid expressing the γ2 subunit plus eGFP from an IRES, and only selected eGFP-
positive cells for recordings (see also (Ralvenius et al., 2015). The transfection mixture 
contained (in µg): 1 αx, 1 βy, 3 γ2/eGFP (used as a marker of successful transfection) or 1 
α2, 1 β3, 3 γ2/eGFP. Whole-cell patch-clamp recordings were made 18 – 36 hrs after 
transfection. Whole-cell patch-clamp recordings of GABA-evoked currents were made at 
room temperature (20 – 24°C) and at a holding potential of -60 mV. Recording electrodes 
were filled with solution containing (in mM): 120 CsCl, 10 EGTA, 10 HEPES (pH 7.40), 4 
MgCl2, 0.5 GTP and 2 ATP. The external solution contained (in mM): 150 NaCl, 10 KCl, 2.0 
CaCl2, 1.0 MgCl2, 10 HEPES (pH 7.4), and 10 glucose. GABA was applied to the recorded 
cell using a manually controlled pulse (4 - 8 s) of a low sub-saturating GABA concentration 
(EC10). EC10 values of GABA were determined for the four GABAAR combinations (α1β2γ2, 
α2β3γ2, α3β3γ2 and α5β2γ2). EC50 values and Hill coefficients (nH) were obtained from fits 
of normalized concentration–response curves to the equation IGABA = Imax [GABA]nH / 
([GABA]nH + [EC50]nH). Imax was determined as the average maximal current elicited by 
saturating concentration of GABA. DZP, CBZ and NDMC were dissolved in DMSO and 
subsequently diluted the day of the experiment in external solution and were co-applied with 
GABA (EC10) without preincubation. Concentration-response curves were fitted to a non-
linear regression using the equation for sigmoidal concentration-response curve with variable 
slope:  
E (C) = Emax ·[C] · nH / ([C]nH + [EC50] ·nH), using GraphPad Prism5. 
Mice 
Experiments were performed in wild-type mice (genetic background C57BL/6J or 
129X1/SvJ), and in homozygous quadruple (H→R) GABAAR point-mutated mice (genetic 
background 129X1/SvJ). Quadruple point-mutated mice were generated by cross breeding 
single point-mutated mice described earlier (Rudolph et al., 1999; Low et al., 2000; Crestani 
et al., 2002). 
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Animal experiments 
All behavioral experiments were performed in 7 - 10 week old female and male mice. Care 
was taken to ensure equal numbers of female and male mice. All behavioral experiments 
were made by a male experimenter, blinded either to the genotype of the mice or to their 
treatment with drug or vehicle. Permission for animal experiments was obtained from the 
Veterinäramt des Kantons Zürich (license numbers 135/2009 and 126/2012). DZP, CBZ and 
NDMC were suspended in 0.9% saline, 1% Tween80 and applied orally in all experiments.  
Neuropathic pain was evoked by applying a chronic constriction injury (CCI; (Bennett & 
Xie, 1988)) to the left sciatic nerve proximal to the trifurcation with three loose (5-0 silk) 
ligatures. Mice, which showed signs of paralysis or which did not develop significant 
hypersensitivity, were excluded from subsequent experiments. Effects of DZP, CBZ and 
NDMC on thermal and mechanical hyperalgesia were assessed one week after surgery. Heat 
hyperalgesia was quantified as the change in the latency of paw withdrawal evoked by 
exposure of the plantar side of one hindpaw to a defined radiant heat stimulus. Mechanical 
hyperalgesia was assessed with electronic von Frey filament #7 (IITC, Woodland Hills, CA). 
Three to four measurements were made for each time point and animal for both heat and 
mechanical hyperalgesia. Percent maximal possible effect (%MPE) was calculated as 
follows:  
%MPE(t) = (E(t)-Epredrug))/(EpreCCI-Epredrug); E(t), paw withdrawal thresholds or latency at 
time point t. Epredrug, E after CCI surgery but before DZP application; EpreCCI, E baseline 
before CCI surgery.  
Locomotor activity was measured in an open field arena (10 cm diameter) equipped with four 
pairs of light beams and photosensors. Drug was applied immediately before placing the 
animal into the recording chamber. Locomotor activity was analyzed for the time interval 
between 72 and 120 min after drug administration. Motor control was assessed with a rotarod 
accelerating from 4 rpm to 40 rpm within 5 min. Sixty min after drug administration mice 
were placed onto the rotarod. Five measurements were taken per mouse. To assess muscle 
relaxation, mice were placed with their forepaws onto a metal horizontal wire placed 20 cm 
above ground. Successes and failures to grab the wire with at least one hindpaw were 
recorded between 60 and 180 min after drug administration.  
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NDMC pharmacokinetics 
Pharmacokinetic properties of NDMC were evaluated after oral administration of 3, 10 and 
30 mg/kg, using the dried blood spot sampling method. This technique allows collecting 
multiple bleeds from the same animal over a large time window (Déglon et al., 2011). Four µl 
of whole blood were collected and spotted onto a filter paper card from Whatman (Dassel, 
Germany) at different time points between 0 and 48 h after NDMC administration. NDMC 
determination was performed using a fully validated LC-MS-MS method as previously 
described (Besson et al., 2013). Pharmacokinetic parameters were estimated by a non-
compartmental method using WinNonlin® version 5.2 (Pharsight, Mountainview, CA, USA). 
Results 
GABAAR subtype selectivity 
We first analyzed potency and efficacy of DZP, CBZ and NDMC as positive allosteric 
modulators of recombinant GABAARs expressed in HEK 293 cells (figure 1). All three 
compounds potentiated currents through α1-, α2-, α3- and α5-GABAARs. Differences were 
observed with respect to the potency and efficacy of the three compounds at the four 
GABAAR types. DZP potentiated currents through all four GABAAR subtypes with an EC50 
between 0.029 and 0.071 µM. CBZ and NDMC were less potent with EC50 values between 
0.40 and 1.1 µM (CBZ) and between 0.49 and 0.81 µM (NDMC), respectively. Pronounced 
differences were found between compounds and GABAAR subtypes with respect to efficacy 
of potentiation. Potentiation by DZP was highest for α3-GABAARs with 237%, while 
potentiation of the other three GABAAR subtypes ranged between 100% and 141%. 
At sub-saturating DZP concentrations (< EC50, which are probably more relevant to 
therapeutic effects) the rank order was α1>> α3> α5>> α2. CBZ had very similar efficacies at 
the four GABAAR subtypes, but at sub-saturating concentrations potentiation followed a 
different rank order with α2>> α5> α1>> α3. NDMC had the best α2-/α1-GABAAR 
selectivity ratio with respect to efficacy. Efficacy was similarly high for α2 and α3 (253 and 
245%) and considerably lower for α1 and α5 (143 and 148%). At sub-saturating 
concentrations, potentiation was highest for α2, followed by α3 and lowest for α5 and α1. 
NDMC thus had the most favorable α2-/α1-GABAAR selectivity profile among the three 
compounds tested. 
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Figure 1. Potentiating effects of DZP, CBZ and NDMC on the four benzodiazepine-sensitive GABAAR 
subtypes. 
Example traces of currents through recombinant α1/β2/γ2, α2/β3/γ2, α3/β3/γ2, and α5/β2/γ2 GABAARs 
transiently expressed in HEK293 cells before drug application (light tract) and in the presence of DZP (1 µM) 
(A), CBZ (20 µM) (B) and NDMC (20 µM) (C) (solid trace). GABA concentration was EC10 for all 
experiments. Scale bars, 2s and 200 pA. Concentration response curves of the drugs obtained for all four 
benzodiazepine-sensitive GABAAR subtypes. Data are mean ± SEM. Curves represent fits to Hill’s equation 
with the baseline fixed to 0. Numbers of cells tested are between 5 - 7 for all data points. 
Sedation 
The improved α2/α1 selectivity profile of NDMC should manifest in a reduced propensity to 
cause sedation. We therefore compared the effects of CBZ and NMDC (3, 10, and 30 mg/kg 
body weight) on locomotor activity in the open field test (figure 2). We performed these tests 
in two mouse strains of different genetic background, namely in C57BL/6J mice, which are 
the standard in most behavioral mouse studies, and in 129X1/SvJ mice, which show higher 
expression levels of α2-GABAARs than C57BL/6 mice (Mulligan et al., 2012). We 
monitored locomotor activity for 6 hours after drug application.  
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Statistical analyses were made for the time period between 72 and 120 min because the pain 
tests described below indicate that this was the time interval of maximal drug effect. In 
C57BL/6 mice, CBZ induced a dose-dependent reduction in locomotor activity, which 
reached a statistically highly significant reduction by 70% at a dose of 30 mg/kg (P <0.001) 
(figure 2 A,B). NDMC did not reduce average locomotor activity at doses up to 10 mg/kg 
(average changes were < 10%). At 30 mg/kg it caused a moderate reduction by 36% (P = 
0.025). Reduction in locomotor activity was even less pronounced in 129X1/SvJ mice. In 
these mice neither, NDMC or its parent compound CBZ caused any measurable reduction in 
locomotor activity (figure 2 C,D). 
Antihyperalgesic actions 
Previous studies from our laboratories had demonstrated an analgesic or antihyperalgesic 
effect of CBZ (Besson et al., 2013). PK/PD analyses had suggested that the antihyperalgesia 
observed in mice following CBZ administration was at least partially mediated by NDMC, 
the main metabolite of CBZ. Therefore, we next verified whether NDMC would indeed 
produce antihyperalgesia. Neuropathic pain was evoked through a chronic constriction injury 
(CCI) of the left sciatic nerve in wild-type mice. Seven to fourteen days after surgery, four 
groups of mice were systemically (per os, p.o.) treated with three different doses of NDMC 
(3, 10, or 30 mg/kg) or with vehicle (figure 3). All mice developed pronounced mechanical 
and heat hyperalgesia 7 - 14 days after CCI surgery. NDMC dose-dependently reduced both 
heat and mechanical hyperalgesia (figure 3 A,B). At the maximum dose applied (30 mg/kg), 
NDMC caused a complete reversal of hyperalgesia. 
We next examined whether this antihyperalgesia was indeed mediated by the benzodiazepine 
binding site of GABAARs. This binding site is formed by an interface between one α and the 
γ2 subunit, and requires the presence of a conserved histidine residue in the GABAAR α 
subunit. To investigate whether this site was indeed responsible for the antihyperalgesia 
observed after NDMC, we made use of quadruple point mutated mice in which all four 
GABAAR α subunits, which can form high affinity benzodiazepine binding site, had been 
point mutated to disrupt this binding site. In these mice NDMC had completely lost its 
antihyperalgesic effects (figure 3 C,D). 
. 
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Figure 2. Comparison of sedative effects by CBZ and NDMC in two different mouse strains 
Effects of per orally applied CBZ (A) and NDMC (B) in C57BL6/J mice and of CBZ (C) and NDMC (D) in 
129X1/SvJ mice on locomotor activity in the open field test. Right side shows statistical analysis. (A) *** 
P<0.001, * P<0.05 significant versus vehicle-treated mice (ANOVA followed by Dunnett’s post hoc test), 
F(3,26)=6.7 (n=8, 7, 7, 7 for vehicle and 3, 10 and 30 mg/kg CBZ-treated mice) and (B) F(3,20)=3.2 (n=6, 5, 6, 
6 for vehicle and NDMC-treated mice). All data points are mean ± SEM. (C) P>0.53, F(3,24)=0.58 (n=7, 7, 7, 6 
for vehicle and 3, 10 and 30 mg/kg CBZ-treated mice) and (D) P>0.78, F(3,23)=0.31 (n=7, 6, 7, 6 for vehicle 
and NDMC-treated mice). All data points are mean ± SEM. 
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Figure 3. Mechanical and thermal antihyperalgesia by per oral NDMC.  
Reversal of hyperalgesia by NDMC assessed with von Frey filaments 7-14 days after CCI surgery. C57BL6/J 
mice were tested for mechanical hyperalgesia (A), right side shows statistical analysis. *** P<0.001, ** P<0.01 
* P<0.05 significant versus vehicle-treated mice (ANOVA followed by Dunnett’s post hoc test), F(3,41)=19.8 
(n=10, 12, 11, 11 for vehicle and 3, 10 and 30 mg/kg NDMC-treated mice). (B) C57BL6/J mice tested for 
thermal hyperalgesia 7-14 days after CCI surgery. Right side shows statistical analysis. *** P<0.001, ** P<0.01 
* P<0.05 significant versus vehicle-treated mice (ANOVA followed by Dunnett’s post hoc test), F(3,49)=15.2 
(n=14, 13, 13, 12 for vehicle and 3, 10 and 30 mg/kg NDMC-treated mice). (C) Mechanical antihyperalgesia by 
NMDC (30 mg/kg) assed in wild-type 129X1/SvJ mice 7-14 days after CCI surgery, right panel shows 
statistical analysis. *** P<0.001, significant versus vehicle-treated mice (unpaired t-test), n=9 and 8 for wild-
type and RRRR mice. (D) Thermal antihyperalgesia by NDMC (30 mg/kg) assed in wild-type 129X1/SvJ mice 
7-14 days after CCI surgery, right side shows statistical analysis. * P<0.05, significant versus vehicle-treated 
mice (unpaired t-test), n=4 and 4 for wild-type and RRRR mice. All data points are mean ± SEM. 
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NDMC pharmacokinetics 
In order to further support that the antihyperalgesia was mediated by NDMC and not by a 
different down-stream metabolite, we measured plasma levels of NDMC with HPLC 
following single oral doses of 3, 10 and 30 mg/kg in three mice per group (figure 4). 
Maximal plasma levels were reached within 2 - 3 hours. Average maximum plasma 
concentrations were 1.2, 1.9, and 3.3 µg/ml. Plasma half-life was between 4.6 and 5.6 hrs.  
 
 
Figure 4. NDMC pharmacokinetics 
NDMC whole blood concentrations (mean ± SEM) over time after p.o. administration (A). Display at a 
logarithmic scale reveals linear elemination kinetics over a large range of concentrations. n=3 per group. 
 
Tab. 1 NDMC PK parameters in whole blood (n=3 mice) 
Dose 
(mg/kg) 
Half-life 
(h) SD Cmax (µg/ml) SD 
AUC 
(h⋅µg/ml) SD Tmax (h) SD 
3 5.6 0.6 1.19 2.53 11.15 1.66 2.0 0.9 
10 4.6 1.6 1.91 1.34 14.72 4.38 3.0 0.0 
30 4.7 0.3 3.31 1.01 32.28 5.09 2.7 0.6 
 
Areas under the curve (AUC) were 11, 15, and 32 h⋅µg/ml for 3, 10, and 30 mg/kg. Increases 
in Cmax and AUC observed with increased doses were thus lower than expected if NDMC 
followed a linear absorption but elimination followed 1st order kinetics. The tmax of about 2.5 
hrs and the half-life of around 5 hrs fitted well with the time course of antihyperalgesia 
following NDMC administration confirming that NDMC did not require further metabolism 
for its antihyperalgesic action.  
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Side effect profile  
The improved α2/α1 selectivity profile of NDMC suggests that NDMC might exert less or 
weaker side effects at antihyperalgesic doses than CBZ or DZP. We therefore tested the same 
three doses of NDMC that had been evaluated for their antihyperalgesic effect for potential 
impairment of motor coordination and muscle strength in wild-type mice (figure 5). 
Impairment of motor coordination and muscle relaxation were assessed in the rotarod test and 
the horizontal wire test, respectively. NDMC showed a dose-dependent trend towards 
improved performance in the rotarod test. In the horizontal wire test, NDMC showed a trend 
towards reduced muscle strength, which was not unexpected as facilitation of α2-GABAARs 
causes muscle relaxation. These results indicate that the improved α2/α1 selectivity profile of 
NDMC obtained in vitro indeed translates into reduced side effects in vivo.  
 
Figure 5. Motor coordination and muscle relaxation.  
(A) Effects of NDMC (0, 3, 10 and 30 mg/kg p.o.) on motor coordination (ANOVA followed by Dunnett’s post 
hoc test), F(3,17)=2.5 (n=5, 5, 5, 5 for vehicle and 3, 10 and 30 mg/kg NDMC-treated mice). (B) Effects of 
NDMC (0, 3, 10 and 30 mg/kg p.o.) on muscle relaxation, (ANOVA followed by Dunnett’s post hoc test), 
F(3,21)=1.4 (n=6, 6, 6, 6 for vehicle and 3, 10 and 30 mg/kg NDMC-treated mice). All data points are mean ± 
SEM. 
 
Discussion 
Diminished synaptic inhibition in the spinal dorsal horn is a common feature of several forms 
of chronic pain. Restoring synaptic inhibition should therefore constitute a rational strategy 
for the treatment of many chronic pain syndromes. Fast synaptic inhibition of spinal dorsal 
horn neurons is mediated by the two amino acids GABA and glycine acting on GABAARs 
and strychnine-sensitive glycine receptors, respectively. While no drugs and very few if any 
tool compounds specifically modulated inhibitory glycine receptors (Laube et al., 2002; 
Yévenes & Zeilhofer, 2011), GABAARs offer many opportunities for pharmacological 
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intervention, including positive allosteric modulators among them the benzodiazepines. 
Previous work from our groups and from several other laboratories has demonstrated that a 
facilitation of fast GABAergic synaptic transmission in the spinal cord effectively reverses 
pathologically heightened pain sensitivity in rodents (reviewed in Zeilhofer et al., 2012). 
Similar antihyperalgesia is however not observed after systemic administration of 
benzodiazepines in humans (Corrigan et al., 2012; Richards et al., 2012). Our recent study 
employing triple GABAAR point mutated mice provides strong evidence that the lack of a 
clinically relevant antihyperalgesic effect of systemically administered benzodiazepines 
originates from dose limiting sedative effects of classical benzodiazepines (Ralvenius et al., 
2015). In these triple point mutated mice, in which only either α1- or α2-GABAAR subtype 
remained benzodiazepine-sensitive, has demonstrated that half maximal sedation (via α1-
GABAARs) occurs already at doses 20 times lower that those required for half maximal 
antihyperalgesia (mediated by via α2-GABAARs). This finding is consistent with human 
studies demonstrating that benzodiazepine-induced sedation occurs in humans already at very 
low levels of receptor occupancy (Pauli et al., 1991). This study has shown that clinically 
relevant antihyperalgesia in human requires the development of benzodiazepine site ligands 
with high efficacy at α2-GABAARs and negligible activity at α1-GABAARs. This concept is 
consistent with two recent studies that showed that classical benzodiazepines (CBZ and 
clonazepam) exert some albeit weak analgesic or antihyperalgesic effects in humans at 
weakly sedating doses (Besson et al., 2015; Vuilleumier et al. 2013). Unequivocal evidence 
for a pain relieving effect in humans will however depend on proof-of-concept studies with 
drugs having a significantly improved α2/α1 selectivity. At present no such compounds have 
been approved for use in humans.  
The present study suggests that NDMC might be suitable compound for human proof-of-
concept trials. NMDC exhibited stronger efficacy at α2-GABAARs than CBZ and DZP. This 
result is largely consistent with previous reports on the affinity and efficacy of CBZ and 
NDMC at GABAAR subtypes expressed in Xenopus oocytes (Jensen et al., 2014; Hammer et 
al., 2015). In mice, NDMC evoked pronounced antihyperalgesia at doses, which did not 
induce significant reductions in locomotor activity. Because NDMC is a naturally occurring 
metabolite of the clinically used benzodiazepine CBZ (Caccia et al., 1979), occurrence of 
new side-effects unknown for CBZ is highly unlikely. At present, it is however unknown 
whether the weak effects NDMC in the open field test predict also low sedative effects in 
humans. CBZ and NDMC exhibit very similar potency and efficacy at sedative α1-
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GABAARs. Furthermore, the efficacy of both compounds at α1-GABAARs is very similar to 
that of DZP, a highly sedating benzodiazepine. Nevertheless, at doses causing significant 
analgesia, NDMC reduced locomotor activity less than its parent compound CBZ (this study) 
and also less than DZP (Knabl et al., 2009). Our previous study in triple point mutated mice 
indicates that locomotor activity in the open field test is not only affected by α1-GABAARs 
but also by α2-GABAARs. While α1-GABAARs reduce activity, activation of α2-GABAARs 
increases activity possibly through their anxiolytic effects (see also chapter 1 figure 3). It is 
thus likely that the smaller impact on locomotor activity of high doses of NDMC results from 
increased activity at α2-GABAARs rather than from reduced activity at α1-GABAARs. This 
interpretation is consistent with results obtained in 129X1/SvJ mice. In these mice expression 
of α2-GABAARs is about twice as high as in C57BL/6J mice that were used for the open 
field tests shown in figure 2 (data not shown). These findings may suggest that NDMC might 
not be less sedating than CBZ or DZP. Assessing the three compounds in triple point mutated 
mice with only α1-GABAARs left benzodiazepine-sensitive should help answering this 
question at least for mice.  
On the positive side, it should be noted that NDMC potentiated currents through α2-
GABAARs already at much lower concentrations than currents through the other three 
GABAAR subtypes tested. It is thus possible that NDMC exerts α2-GABAAR-mediated 
antihyperalgesia already occur at doses that are devoid of significant sedative effects. 
Whether the shift in potency of NDMC at α2-GABAARs that was observed in vitro translates 
into clinically significant analgesia at non-sedative doses in humans, remains to be 
confirmed. 
In summary, our study shows that NDMC exhibits an improved α2/α1-GABAAR selectivity 
profile in vitro. Our behavioral experiments suggest that this improved molecular profile 
translates to the in vivo situation. Whether the improvement is large enough to warrant a 
proof-of-concept study in human volunteers or patients remains to be determined. 
 
EXPERIMENTAL SECTION 
- 104 - 
Author contributions 
WTR performed all behavior tests, except initial antihyperalgesia tests, which were done by 
MB and AM. MAA did the electrophysiological experiments. MB and AM did the NDMC 
analytics and analyzed the data. MAA performed and analyzed the electrophysiology 
experiments. HUZ designed experiments, analyzed data and wrote the manuscript. All 
authors made comments on the manuscript. 
 
Acknowledgements 
This study was in part supported by from the Special Program on University Medicine 
(33CM30) of the Swiss National Science Foundation 
 
EXPERIMENTAL SECTION 
- 105 - 
References 
1. Bennett GJ, Xie YK (1988) A peripheral mononeuropathy in rat that produces disorders of pain 
sensation like those seen in man. Pain 33:87-107. 
2. Besson M, Daali Y, Di Lio A, Dayer P, Zeilhofer HU, Desmeules J (2013) Antihyperalgesic effect of 
the GABAA ligand clobazam in a neuropathic pain model in mice: a pharmacokinetic-
pharmacodynamic study. Basic Clin Pharmacol Toxicol 112:192-197. 
3. Besson M, Matthey A, Daali Y, Poncet A, Vuillemier P, Curatolo M, Zeilhofer HU, Desmeules J 
(2015) GABAergic modulation in central sensitization in humans: a randomized placebo-controlled 
pharmacokinetic-pharmacodynamic study comparing clobazam with clonazepam in healthy 
volunteers. Pain 156:397-404. 
4. Beyer C, Roberts LA, Komisaruk BR (1985) Hyperalgesia induced by altered glycinergic activity at 
the spinal cord. Life Sci 37:875-882. 
5. Caccia S, Ballabio M, Guiso G, Zanini MG (1979) Gas-liquid chromatographic determination of 
clobazam and n-desmethyl-clobazam in plasma. J Chromatography 164:100-105. 
6. Corrigan R, Derry S, Wiffen PJ, Moore RA (2012) Clonazepam for neuropathic pain and 
fibromyalgia in adults. Cochrane Database Syst Rev 5:CD009486. 
7. Crestani F, Keist R, Fritschy JM, Benke D, Vogt K, Prut L, Bluthmann H, Möhler H, Rudolph U 
(2002) Trace fear conditioning involves hippocampal α5 GABAA receptors. Proc Natl Acad Sci U S 
A 99:8980-8985. 
8. Déglon J, Thomas A, Daali Y, Lauer E, Samer C, Desmeules J, Dayer P, Mangin P, Staub C (2011) 
Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic 
study of flurbiprofen and its metabolite. J Pharm Biomed Anal 54:359-367 
9. Di Lio A, Benke D, Besson M, Desmeules J, Daali Y, Wang ZJ, Edwankar R, Cook JM, Zeilhofer 
HU (2011) HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is 
antihyperalgesic in mouse models of inflammatory and neuropathic pain. Neuropharmacology 
60:626-632. 
10. Hammer H, Ebert B, Jensen H, Jensen AA (2015) Functional Characterization of the 1,5-
Benzodiazepine Clobazam and Its Major Active Metabolite N-Desmethylclobazam at Human 
GABAA Receptors Expressed in Xenopus laevis Oocytes. PLoS One 10:e0120239. 
11. Hofmann M, Kordas KS, Gravius A, Bolcskei K, Parsons CG, Dekundy A, Danysz W, Dezsi L, 
Wittko-Schneider IM, Saghy K, Gyertyan I, Horvath C (2012) Assessment of the effects of NS11394 
and L-838417, α2/3 subunit-selective GABAA [corrected] receptor-positive allosteric modulators, in 
tests for pain, anxiety, memory and motor function. Behav Pharmacol 23:790-801. 
12. Jensen HS, Nichol K, Lee D, Ebert  B (2014) Clobazam and its active metabolite N-
desmethylclobazam display significantly greater affinities for α₂- versus α₁-GABAA-receptor 
complexes. PLoS One 9:e88456. 
13. Knabl J, Zeilhofer UB, Crestani F, Rudolph U, Zeilhofer HU (2009) Genuine antihyperalgesia by 
systemic diazepam revealed by experiments in GABAA receptor point-mutated mice. Pain 141:233-
238. 
14. Knabl J, Witschi R, Hösl K, Reinold H, Zeilhofer UB, Ahmadi S, Brockhaus J, Sergejeva M, Hess A, 
Brune K, Fritschy J-M, Rudolph U, Möhler H, Zeilhofer HU (2008a) Reversal of pathological pain 
through specific spinal GABAA receptor subtypes. Nature 451:330-334. 
15. Laube B, Maksay G, Schemm R, Betz H (2002) Modulation of glycine receptor function: a novel 
approach for therapeutic intervention at inhibitory synapses? Trends Pharmacol Sci 23:519-527. 
16. Löw K, Crestani F, Keist R, Benke D, Brunig I, Benson JA, Fritschy JM, Rülicke T, Bluethmann H, 
Mohler H, Rudolph U (2000) Molecular and neuronal substrate for the selective attenuation of 
anxiety. Science 290:131-134. 
17. Mulligan MK, Wang X, Adler AL, Mozhui K, Lu L, Williams RW (2012) Complex control of 
GABAA receptor subunit mRNA expression: variation, covariation, and genetic regulation. PLoS One 
7:e34586. 
EXPERIMENTAL SECTION 
- 106 - 
18. Munro G, Ahring PK, Mirza NR (2009) Developing analgesics by enhancing spinal inhibition after 
injury: GABAA receptor subtypes as novel targets. Trends Pharmacol Sci 30:453-459. 
19. Nickolls S, Mace H, Fish R, Edye M, Gurrell R, Ivarsson M, Pitcher T, Tanimoto-Mori S, Richardson 
D, Sweatman C, Nicholson J, Ward C, Jinks J, Bell C, Young K, Rees H, Moss A, Kinloch R, 
McMurray G (2011) A Comparison of the α2/3/5 Selective Positive Allosteric Modulators L-838,417 
and TPA023 in Preclinical Models of Inflammatory and Neuropathic Pain. Adv Pharmacol Sci 
2011:608912. 
20. Paul J, Yevenes GE, Benke D, Di Lio A, Ralvenius WT, Witschi R, Scheurer L, Cook JM, Rudolph 
U, Fritschy JM, Zeilhofer HU (2014) Antihyperalgesia by α2-GABAA receptors occurs via a genuine 
spinal action and does not involve supraspinal sites. Neuropsychopharmacology 39:477-487. 
21. Pauli S, Farde L, Halldin C, Sedvall G (1991) Occupancy of the central benzodiazepine receptors 
during benzodiazepine treatment determined by PET. European Neuropsychopharmacology 1:229-
231. 
22. Ralvenius WT, Benke D, Acuña MA, Rudolph U, Zeilhofer HU (2015) Analgesia and unwanted 
benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABAA 
Receptor Subtype. Nature Communications, in press. 
23. Reichl S, Augustin M, Zahn PK, Pogatzki-Zahn EM (2012) Peripheral and spinal GABAergic 
regulation of incisional pain in rats. Pain 153:129-141. 
24. Richards BL, Whittle SL, Buchbinder R (2012) Muscle relaxants for pain management in rheumatoid 
arthritis. Cochrane Database Syst Rev 1:CD008922. 
25. Roberts LA, Beyer C, Komisaruk BR (1986) Nociceptive responses to altered GABAergic activity at 
the spinal cord. Life Sci 39:1667-1674. 
26. Rudolph U, Knoflach F (2011) Beyond classical benzodiazepines: novel therapeutic potential of 
GABAA receptor subtypes. Nat Rev Drug Discov 10:685-697. 
27. Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H, 
Möhler H (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acidA receptor 
subtypes. Nature 401:796-800. 
28. Sivilotti L, Woolf CJ (1994) The contribution of GABAA and glycine receptors to central 
sensitization: disinhibition and touch-evoked allodynia in the spinal cord. J Neurophysiol 72:169-179. 
29. Tan KR, Brown M, Labouebe G, Yvon C, Creton C, Fritschy JM, Rudolph U, Lüscher C (2010) 
Neural bases for addictive properties of benzodiazepines. Nature 463:769-774. 
30. Tappe-Theodor A, Kuner R (2014) Studying ongoing and spontaneous pain in rodents--challenges 
and opportunities. Eur J Neurosci 39:1881-1890. 
31. Vuilleumier PH, Besson M, Desmeules J, Arendt-Nielsen L, Curatolo M (2013) Evaluation of anti-
hyperalgesic and analgesic effects of two benzodiazepines in human experimental pain: a randomized 
placebo-controlled study. PLoS ONE 8:e43896. 
32. Yévenes GE, Zeilhofer HU (2011) Allosteric modulation of glycine receptors. Br J Pharmacol 
164:224-236. 
33. Zeilhofer HU, Benke D, Yévenes GE (2012) Chronic pain states: pharmacological strategies to 
restore diminished inhibitory spinal pain control. Annu Rev Pharmacol Toxicol 52:111-133. 
 
 
GENERAL DISCUSSION 
- 107 - 
GENERAL DISCUSSION  
Benzodiazepines have been used for decades to treat humans suffering from a variety of brain 
disorders including anxiety, insomnia and epilepsy. Attempts to develop benzodiazepines 
with increased selectivity for non-α1GABAA receptors have initially been made to reduce the 
side effects, i.e. to develop anxioselective, non-sedating benzodiazepines. Recently, several 
reports suggest that such novel subtype-selective benzodiazepines might also be used for the 
treatment of diseases which do not benefit from classical benzodiazepines, such as 
schizophrenia, depression and stroke (Rudolph and Knoflach, 2011). One such potential new 
indication is also chronic pain. The data presented in this thesis support the idea that novel 
benzodiazepines with selective activity at the α2-GABAA receptors (or in addition at α3-
GABAA receptors) should be well-suited for the treatment of chronic pain. This concept is 
well in-line with previous preclinical studies of our laboratory and from others (Knabl et al., 
2008; Munro et al., 2008; Knabl et al., 2009; Di Lio et al., 2011; Nickolls et al., 2011; 
Hofmann et al., 2012; Besson et al., 2013; Paul et al., 2014; de Lucas et al., 2015).  
All these studies clearly indicate that benzodiazepine site ligands with a high intrinsic activity 
at α2-GABAA receptors and low activity at α1-GABAA receptors reduce inflammatory and 
neuropathic hyperalgesia in mice and rats. The great majority of these studies, including most 
of the experiments performed in our laboratory, used withdrawal responses to quantify 
antihyperalgesia. Although changes in these responses correlate in general well with pain 
perception, they do not necessarily allow the conclusion that the drugs under study do also 
reduce pain sensation. Furthermore, these test measure threshold responses only, and may be 
of limited value for the assessment of ongoing and suprathreshold pain. Nevertheless, several 
experiments done in our laboratory indicate that activation of α2-GABAA receptors does not 
only interfere with spinally coordinated withdrawal responses but also with supraspinal pain 
processing. Results very similar to those obtained with withdrawal response were seen in the 
formalin test, which exposes the animal to suprthreshold pain and triggers supraspinally 
coordinated behaviors such as biting or licking responses. Furthermore, one of the first “α1-
sparing” benzodiazepine site agonists, L-838,417 (McKernan et al., 2000), reduced not only 
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withdrawal responses in inflamed rats but also reduced pain-correlated brain activity in 
BOLD fMRI experiments (Knabl et al., 2008). To further substantiate our hypothesis that 
activation of α2-GABAA receptors reduces not only spinally-mediated pain responses but 
also conscious pain experience, conditioned place preference experiments (King et al., 2009) 
might be employed in the future.  
Throughout most of the thesis, I refer to the pain suppressing effect of subtype selective 
benzodiazepines as “antihyperalgesia”. This is meant to emphasize the point that these 
compounds do not suppress acute nociceptive pain (i.e. in our experiments they have no 
effect on pain thresholds in the contralateral non-inflamed or non-injured paw). This term 
also acknowledges the fact that what is measured in our experiments is mostly a change in 
heightened sensitivity to noxious stimuli, usually called hyperalgesia. The use of the term 
“antihyperalgesia” should however not imply that these compounds would not interfere with 
on-going pain in inflammatory or neuropathic condition. The conditioned place preference 
experiments mentioned above will help to address also this point. 
Neuropathy and inflammation can cause diminished inhibition in the spinal dorsal horn 
through a variety of mechanisms (Zeilhofer et al., 2009). In all cases when diminished 
inhibition and pain occur through reduce responsiveness of neurotransmitter receptors, 
reduced synthesis or release of GABA, it is conceivable that drugs facilitating the activity of 
GABAA receptors would alleviate pain. However, when diminished inhibition results from 
disrupted chloride homeostasis, the case is more complicated. A previous report has 
suggested that the increase in intracellular chloride concentration following peripheral nerve 
damage can turn the effect of GABAA receptor activation from inhibition to excitation (Coull 
et al., 2003). In this case, facilitation of GABAA receptors would increase rather than 
alleviate pain. It should be pointed out that in none of our experiments we did observe any 
evidence for a pronociceptive effect of benzodiazepine site ligands. This lack of a pain 
enhancing effect is also consistent with a recent report from Allan Basbaum’s laboratory, 
which shows that transplantation of GABAergic precursor cells into the spinal cord of 
neuropathic mice reverses pathological pain (Bráz et al., 2012). These results do not 
challenge the concept of a disturbance of chloride homeostasis in neuropathic pain. They 
rather suggest that the inhibitory effect of GABAergic input is weakened but does not reverse 
into excitation. Nevertheless, a combination with positive allosteric modulators of KCC2 
which promote restoring physiological chloride homeostasis may increase the therapeutic 
efficacy of GABAergic drugs in neuropathic pain patients (Price and Prescott, 2015).  
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A question central to the translational aspect of this thesis is whether facilitation of GABAA 
receptors does also have an impact on pain in humans. Classical non-selective 
benzodiazepines do not exert clinically relevant analgesia in patients (Corrigan et al., 2012; 
Richards et al., 2012). Our data obtained in the triple GABAA receptor point mutated mice 
suggest dose-limiting sedation as the major reason for the absence of clinically relevant 
analgesic properties of classical benzodiazepines in human patients. However, species 
differences cannot be fully excluded a priori. Evidence supporting the translatability comes 
from several different directions. Previous studies from our laboratory have demonstrated 
that α2-GABAA receptor-mediated antihyperalgesia originates largely, if not exclusively, 
from a spinal site of action (Paul et al., 2014). A morphological study by (Waldvogel et al., 
2010) analyzed the expression pattern of the GABAA receptor subunits in the human CNS. 
The expression of all α subunits, of β2/3 and of the γ2 subunit reported in this study is 
remarkably similar to what we and others have previously reported for mice and rats 
(Bohlhalter et al., 1996; Paul et al., 2012). Other supporting evidence comes from a human 
genetics study. Smith et al. (Smith et al., 2012) tested the association of more than 350 genes 
with fibromyalgia in 496 patients and 348 controls. Two SNPs in the GABRB3 gene, which 
encodes for the GABAA receptor β3 subunit, showed the strongest and seventh strongest 
association among a total of 2760 SNPs tested. Because the β3 subunit is contained in most 
α2-GABAA receptors, this finding supports a critical role of α2-GABAA receptors also in 
human pain processing. Finally, direct evidence supporting a pain relieving effect of 
benzodiazepine site ligands also in humans comes from recent studies by (Vuilleumier et al., 
2013; Besson et al., 2015), who tested the effects of two rather weakly sedating 
benzodiazepines, clobazam and clonazepam, on experimental pain in human volunteers. Both 
studies report weak but statistically significant analgesic or antihyperalgesic effects at mildly 
sedating doses.  
Given the great promises of preclinical studies it is surprising that none of the non- or less 
sedative benzodiazepine site agonists developed by pharmaceutical industry got approved for 
human therapy. The three most promising compounds in development probably were MRK-
409, TPA023 and TPA023B, all developed by Merck Sharp & Dohme to treat anxiety 
(Atack, 2010). Unfortunately, in humans MRK-409 was sedative at relatively low levels of 
receptor occupancy due to remaining agonistic activity the benzodiazepine binding site of 
α1GABAA receptors. TPA023 lacks α1 efficacy, but the human trial with this compounds 
was terminated due to unexpected toxicity issues. At least one of the compounds, TPA023B 
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showed no signs of sedation in humans (Atack et al., 2011), and was last reported on in 2011 
to be in Phase I clinical trials against anxiety disorders and schizophrenia (Rudolph and 
Knoflach, 2011). Concert Pharmaceuticals has been developing a drug called CTP-354, 
which is a deuterated version of L-838,417, for the treatment of spasticity (concert 
pharmaceuticals, 2015). The company was expecting to launch two separate Phase II trials 
last year, one evaluating the drug for treatment of spasticity caused by spinal cord injury and 
the other spasticity caused by multiple sclerosis.  
Although TPA023B might be at least a useful compound to test antihyperalgesic efficacy in 
human pain patients, publicly available safety data are not sufficient to obtain permission for 
clinical studies. One of the aims of this thesis was therefore to explore alternative strategies 
based on the assumption that benzodiazepine metabolites occurring in humans after 
administration of a classical benzodiazepine might exert a better GABAA receptor subtype 
selectivity profile. A pharmacodynamic/pharmacokinetic study on clobazam in mice revealed 
that the antihyperalgesic effects seen after clobazam administration were not caused by 
clobazam itself but by an active metabolite (Besson et al., 2013). The major metabolite of 
clobazam in man is N-desmethyl clobazam (Caccia et al., 1979) As analyzed in detail in this 
thesis, N-desmethyl clobazam does not only reduces antihyperalgesia in mice but also 
exhibits a more favorable selectivity ratio at α2 versus α1 GABAA receptors. Because N-
desmethyl clobazam is a naturally occurring metabolite of clobazam, occurrence of new side-
effects unknown from clobazam is highly unlikely. It may thus be considered a suitable 
compound proof-of-concept studies in humans.  
Alternative strategies to further promote the translation of the concept of GABAergic 
analgesia to patients may involve the testing of suitable compounds in non-rodent animal 
species. In particular dogs often suffer from chronic pain conditions, mainly caused by 
degenerative joint diseases. TPA023B, has already been given to dogs in the context of 
pharmacokinetic studies and was well tolerated (Atack et al., 2011). It should therefore be 
possible to evaluate this compound in veterinary patients. 
In summary, the use of the triple GABAA receptor point-mutated mice has allowed to predict 
in vivo actions of yet to be developed subtype-selective agents with unprecedented precision. 
The identification of N-desmethyl clobazam as a potentially suitable compound for clinical 
proof-of-concept studies may foster the translation of these discoveries to clinical therapy.  
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